

# Highly Potent and Selective MT<sub>2</sub> Melatonin Receptor Full Agonists from Conformational Analysis of 1-Benzyl-2-acylaminomethyl-tetrahydroquinolines

Gilberto Spadoni,<sup>†</sup> Annalida Bedini,<sup>†</sup> Simone Lucarini,<sup>†</sup> Michele Mari,<sup>†</sup> Daniel-Henri Caignard,<sup>‡</sup> Jean A. Boutin,<sup>‡</sup> Philippe Delagrèze,<sup>‡</sup> Valeria Lucini,<sup>§</sup> Francesco Scaglione,<sup>§</sup> Alessio Lodola,<sup>||</sup> Franca Zanardi,<sup>||</sup> Daniele Pala,<sup>||</sup> Marco Mor,<sup>||</sup> and Silvia Rivara<sup>\*,||</sup>

<sup>†</sup>Dipartimento di Scienze Biomolecolari, Università degli Studi di Urbino “Carlo Bo”, Piazza Rinascimento 6, I-61029 Urbino, Italy


<sup>‡</sup>Institut de Recherches Servier, 125 Chemin de Ronde, F-78290 Croissy sur Seine, France

<sup>§</sup>Dipartimento di Biotecnologie Mediche e Medicina Traslazionale, Università degli Studi di Milano, Via Vanvitelli 32, I-20129 Milano, Italy

<sup>||</sup>Dipartimento di Farmacia, Università degli Studi di Parma, Parco Area delle Scienze 27/A, I-43124 Parma, Italy


## S Supporting Information

**ABSTRACT:** Molecular superposition models guided the design of novel melatonin receptor ligands characterized by a 2-acylaminomethyltetrahydroquinoline scaffold. Starting from the structure of *N*-anilinoethylamide ligands, the flexible chain was conformationally constrained to reproduce the bioactive conformation of melatonin. Structure–activity relationships were investigated, focusing on the substituent at the nitrogen atom, the position of the methoxy group, and the replacement of the amide side chain by urea and thiourea groups. The compounds were tested for binding affinity and intrinsic activity at human MT<sub>1</sub> and MT<sub>2</sub> receptors. Structural optimization resulted in *N*[(1-benzyl-1,2,3,4-tetrahydro-5-methoxyquinolin-2-yl)methyl]propionamide (UCM1014), with picomolar MT<sub>2</sub> binding affinity ( $K_i = 0.001$  nM), more than 10000-fold selectivity over the MT<sub>1</sub> receptor, and a full agonist profile (GTPγS test), being the most potent MT<sub>2</sub>-selective full agonist reported to date. Molecular dynamics simulations provided a rationale for high binding affinity, stereoselectivity, and agonist behavior of these novel melatonin receptor ligands based on superposition models and conformational preference.



## INTRODUCTION

Melatonin (*N*-acetyl-5-methoxytryptamine, **1** in Figure 1) is a neurohormone primarily secreted by the pineal gland following a circadian rhythm, with peak concentrations at night. Melatonin exerts an important role in the control of circadian rhythms and in sleep regulation. Additionally, it has been shown to influence a variety of physiological functions such as the activity of the immune system and of reproductive organs, the homeostasis of the cardiovascular system, and pain perception.<sup>1</sup> Melatonin administration has shown beneficial effects in animal models of different diseases<sup>2,3</sup> such as stroke, cancer, and neurodegenerative diseases, and a number of clinical trials have been set up to evaluate its potential in different human pathological conditions.<sup>4</sup> Melatonin has a pleiotropic mechanism of action as it displays antioxidant effects, activates membrane receptors, and interacts with



**Figure 1.** Structures of melatonin (**1**) and tetrahydrobenzo[*cd*]indole agonist **2**; general formulas of *N*-anilinoethylamides and of conformationally constrained tetrahydroquinoline compounds.


Received: July 8, 2015

intracellular constituents such as calmodulin and the MT<sub>3</sub> binding site.<sup>5</sup> In mammals, melatonin activates the MT<sub>1</sub> and MT<sub>2</sub> G protein-coupled receptors which are mainly expressed in the central nervous system but are also present in peripheral organs and tissues.<sup>6,7</sup>

Melatonin is classified as a dietary supplement in many countries and it is widely used as a sleep inducer or to promote the resynchronization of disrupted circadian rhythms such as in the case of jet lag. A prolonged-release melatonin formulation has been approved as a drug for insomnia therapy.<sup>8</sup> Besides the natural ligand, MT<sub>1</sub>/MT<sub>2</sub> nonselective melatonin receptor agonists have been developed and are available for the treatment of different pathologies. Ramelteon is used to treat insomnia, tasimelteon has been granted marketing authorization for non-24-h sleep–wake disorder, and agomelatine, also endowed with 5HT<sub>2c</sub> antagonism, is approved for major depression.<sup>9,10</sup> Medicinal chemistry research has also led to the discovery of MT<sub>1</sub> or MT<sub>2</sub> subtype-selective ligands as well as of compounds with different intrinsic activities, with partial agonists, antagonists, or inverse agonists reported in the literature.<sup>11,12</sup> The availability of pharmacological tools and of receptor knockout animals has allowed the functional characterization of MT<sub>1</sub> and MT<sub>2</sub> receptors, that, even if far from being complete, has highlighted some differential roles for the two subtypes. Indeed, the MT<sub>1</sub> receptor is mainly involved in inhibition of neuronal firing in mice suprachiasmatic nucleus (SCN), inhibition of prolactin secretion in photoperiodic species, modulation of visual function, and vasoconstriction in rat caudal arteries. On the other hand, studies on animal models showed that MT<sub>2</sub> receptor activation mediates the phase-shifting effect of melatonin in the SCN, is involved in promotion of non-REM sleep in mice, and mediates arterial vasodilation.<sup>13</sup>

During our studies on melatonin receptor ligands, we identified *N*-anilinoethylamides (Figure 1) as a class of compounds that could be easily modulated to provide different receptor subtype selectivity and intrinsic activity profiles.<sup>14</sup> Indeed, substituents with limited size on the aniline nitrogen (e.g., a methyl group) gave potent MT<sub>1</sub>/MT<sub>2</sub> nonselective agonists, while bulkier substituents led to selectivity for the MT<sub>2</sub> receptor and to limited intrinsic activity, moving toward a partial agonist or an antagonist behavior. Selectivity for the MT<sub>1</sub> receptor could be obtained replacing the methoxy group with a lipophilic arylalkoxy chain (e.g., a phenylbutyloxy substituent).<sup>15</sup>

Starting from the structure of *N*-anilinoethylamides, characterized by high conformational freedom, we designed a novel series of conformationally constrained MT<sub>2</sub>-selective agonists. Among the different possible ring closures, inclusion of the carbon atom bound to the aniline nitrogen into a six-membered ring gives tetrahydroquinoline derivatives carrying an acylaminomethyl side chain in position 2 (Figure 1, bottom). Indeed, preliminary molecular modeling studies suggested that 2-acylaminomethyltetrahydroquinolines could reproduce the putative bioactive conformation of melatonin, which had been previously identified and validated by means of pharmacophore models and synthesis of potent conformationally constrained compounds.<sup>16,17</sup> In particular, superposition of melatonin and the tricyclic 1,3,4,5-tetrahydrobenzo[*cd*]indole agonist **2** (Figure 1) pointed out that the two fused six-membered rings could represent a suitable scaffold in which carbon 2a of compound **2** can be replaced with the tetrahydroquinoline nitrogen (Figure 2). Insertion of suitable




**Figure 2.** Superposition of compound **2** (light blue carbons) to the putative bioactive conformation of melatonin (**1**, yellow carbons) and effect of substituents on MT<sub>1</sub> and MT<sub>2</sub> binding affinity and intrinsic activity.

substituents on the tetrahydroquinoline scaffold could in principle allow the modulation of binding affinity, receptor subtype selectivity, and intrinsic activity toward the desired profile by fulfilling the structural requirements outlined by structure–activity relationships (SARs) and 3D-QSAR studies.<sup>18</sup> It is well recognized that the presence of the methoxy group in position 5 of the indole ring of melatonin increases MT<sub>1</sub> and MT<sub>2</sub> binding affinity and intrinsic activity, and insertion of a substituent in position 2 (e.g., a phenyl ring, a iodine atom) increases binding affinity. On the other hand, a substituent in position 1 or 2 occupying a region of space located outside the plane defined by the indole ring leads to MT<sub>2</sub>-selectivity and to an antagonist behavior.

Herein we report the synthesis and evaluation of the binding affinity and intrinsic activity at human MT<sub>1</sub> and MT<sub>2</sub> receptors of 2-acylaminomethyltetrahydroquinoline derivatives. We analyzed their SARs focusing the attention on the role of substituents on the nitrogen atom, of the methoxy group, and on the importance of side chain length and terminal acyl group. Moreover, stereoselectivity is also discussed in light of the ability of enantiomers to reproduce the active conformation of melatonin.


## CHEMISTRY

2-Methanamidotetrahydroquinolines **6a–g** (Scheme 1) were prepared by hydrogenation (4 atm, 60 °C) of the corresponding 2-cyanoquinoline **4a–d** in the presence of Raney-Ni and ammonia (a contemporary reduction of the cyano group and of the heterocycle ring occurs), followed by *N*-acylation with the suitable acylating reagent (acetic or propionic anhydride, cyclopropanecarbonyl or cyclobutanecarbonyl chloride). 2-Quinolinecarbinitrile (**4d**) is commercially available, whereas the methoxy-2-cyanoquinolines **4a–c** were prepared by *O*-methylation of the corresponding hydroxy-2-cyanoquinolines **3a**,<sup>19</sup> **3b**,<sup>20</sup> and **3c**<sup>21</sup> with methyl iodide. *N*-[(5-Methoxyquinolin-2-yl)methyl]propionamide (**7**) was obtained by Raney-Ni catalyzed hydrogenation (3.5 atm, rt) of the cyanoquinoline **4a** and subsequent *N*-acylation of the primary amine with propionic anhydride (Scheme 1). The (tetrahydroquinolin-2-yl)ureido derivatives **6h–k** were prepared by reacting the suitable crude (1,2,3,4-tetrahydroquinolin-2-yl)-methanamine (**5a** or **5d**) with the appropriate ethyl isocyanate. The *N*<sup>1</sup>-methyl- or *N*<sup>1</sup>-benzyl-(tetrahydroquinolin-2-yl)ureido derivatives (**6l–n**) were prepared by *N*<sup>1</sup>-alkylation of **6h** or **6i** with methyl iodide or benzyl bromide (Scheme 1). The *N*<sup>1</sup>-

Scheme 1<sup>a</sup>

<sup>a</sup>Reagents and conditions: (a) CH<sub>3</sub>I, K<sub>2</sub>CO<sub>3</sub>, acetone, rt, 15 h, yield 74–95%; (b) H<sub>2</sub> (4 atm), Raney-Ni, 2 M NH<sub>3</sub> in EtOH, THF, 60 °C, 16 h; (c) anhydride or acyl chloride, Et<sub>3</sub>N, THF, rt, 1 h, two steps (b,c) yield 34–73%; (d) ethyl isocyanate or ethyl isothiocyanate, CH<sub>2</sub>Cl<sub>2</sub>, rt, 30 min, two steps (b,d) yield 49–65%; (e) CH<sub>3</sub>I, NaHCO<sub>3</sub>, MeOH, 50 °C, 24 h, yield 77%; (f) benzyl bromide, Et<sub>3</sub>N, toluene, reflux, 2 h, yield 88%; (g) H<sub>2</sub> (3.5 atm), Raney-Ni, 2N NH<sub>3</sub> in MeOH, rt, 30 min; (h) propionic anhydride, Et<sub>3</sub>N, THF, rt, 1 h, two steps yield 48%.

alkylated tetrahydroquinolines **8a–l** were obtained by N<sup>1</sup>-alkylation of the suitable (alkanamidomethyl)-tetrahydroquinoline **6a–g** with benzyl bromide (**8a–g**), methyl iodide (**8h–i**), phenylethyl bromide (**8j**), 1-iodopropane (**8k**), or 2-chloro-N-methylacetamide (**8l**) in the presence of a base (Scheme 2). The N<sup>1</sup>-phenyl-tetrahydroquinoline derivative **11**

Scheme 2<sup>a</sup>

<sup>a</sup>Reagents and conditions: (a) benzyl bromide, Et<sub>3</sub>N, toluene, reflux, 2 h, yield 54–92%; (b) CH<sub>3</sub>I, NaHCO<sub>3</sub>, MeOH, 50 °C, 24 h, yield 87–95%; (c) phenylethyl bromide, Et<sub>3</sub>N, toluene/DMF, 90 °C, 18 h, yield 68%; (d) 1-iodopropane, Et<sub>3</sub>N, toluene/DMF, 90 °C, 18 h, yield 43%; (e) 2-chloro-N-methylacetamide, Et<sub>3</sub>N, DMF, 100 °C, 16 h, yield 26%.

was prepared by N-arylation of 2-cyanotetrahydroquinoline<sup>22</sup> **9** with benzyne (generated by reaction of 2-(trimethylsilyl)phenyl triflate with cesium fluoride), under very mild reaction conditions. Hydrogenation of the cyano group of compound **10** and concomitant acylation of the intermediate primary amine completed the synthesis of **11** (Scheme 3). To prepare the thioureido derivative **13**, 1-methyl-1,2,3,4-tetrahydroquinoline-2-carbonitrile<sup>23</sup> **12** was submitted to hydrogenation


(Raney-Ni, 4 atm) and the corresponding free amine was treated with ethyl isothiocyanate (Scheme 3).

Finally, the higher homologue **15** was obtained by reduction of (1,2,3,4-tetrahydroquinolin-2-yl)acetonitrile,<sup>24</sup> followed by N-acylation of the intermediate amine with propionic anhydride and final N<sup>1</sup>-benzylation of the tetrahydroquinoline skeleton of intermediate **14** (Scheme 4).


## RESULTS AND DISCUSSION

The newly synthesized tetrahydroquinoline derivatives were evaluated for their binding affinity and intrinsic activity at human MT<sub>1</sub> and MT<sub>2</sub> receptors stably transfected in Chinese hamster ovary (CHO) cells using 2-[<sup>125</sup>I]iodomelatonin as radioligand, and the results are reported in Table 1.

Compound **8i**, having a methyl group on the tetrahydroquinoline nitrogen, showed MT<sub>1</sub> and MT<sub>2</sub> binding affinities in the same range as melatonin, with an MT<sub>2</sub> full agonist behavior, while at the MT<sub>1</sub> receptor it behaved as a partial agonist. These data confirm tetrahydroquinoline as an efficient conformationally constrained analogue of anilinoethylamide and a valuable bioisoster for the indole scaffold of melatonin. Removal of the methyl group on the nitrogen atom (**6d**) caused a 10-fold reduction of MT<sub>1</sub> and MT<sub>2</sub> binding affinity and a decreased ability to stimulate the receptors, with lower E<sub>max</sub> and EC<sub>50</sub> values. This finding is in line with what observed in the N-anilinoethylamide series in which removal of the N-methyl group reduced both binding affinity and intrinsic activity.<sup>14</sup> Bulkier substituents on the nitrogen atom, such as a phenyl ring (**11**) and especially a benzyl group (**8d**), were detrimental for MT<sub>1</sub> binding affinity. On the contrary, these substituents led to an increase in MT<sub>2</sub> binding affinity compared to the methyl derivative **8i**, with limited reduction of intrinsic activity (E<sub>max</sub>). The benzyl derivative **8d** has more than 400-fold selectivity for the MT<sub>2</sub> receptor and acts as a potent MT<sub>2</sub> partial agonist. These data further support that the behavior of tetrahydroquinolines is consistent with SARs obtained from classical melatonin receptor ligands, given the MT<sub>2</sub> selectivity and reduced intrinsic activity provided by the benzyl substituent.<sup>18,25</sup> Elongation of the side chain in position 2, with

Scheme 3<sup>a</sup>

<sup>a</sup>Reagents and conditions: (a) NaCNBH<sub>3</sub>, AcOH, 40 °C, 16 h, yield 48%; (b) 2-(trimethylsilyl)phenyl triflate, CsF, CH<sub>3</sub>CN, rt, 16 h, yield 55%; (c) H<sub>2</sub> (4 atm), Raney-Ni, propionic anhydride, THF, 60 °C, 5 h, yield 69%; (d) NaCNBH<sub>3</sub>, 37% HCHO, MeOH/AcOH, rt, 16 h; (e) H<sub>2</sub> (4 atm), Raney-Ni, 2 M NH<sub>3</sub> in EtOH, THF, rt, 24 h; (f) ethyl isothiocyanate, CH<sub>2</sub>Cl<sub>2</sub>, rt, 16 h, two steps yield 52%.

Scheme 4<sup>a</sup>

<sup>a</sup>Reagents and conditions: (a) H<sub>2</sub> (4 atm), Raney-Ni, 2 M NH<sub>3</sub> in EtOH, THF, 60 °C, 6 h; (b) propionic anhydride, Et<sub>3</sub>N, THF, rt, 1 h, two steps yield 57%; (c) benzyl bromide, Et<sub>3</sub>N, toluene, reflux, 2 h, yield 70%.

insertion of an ethylene spacer between the amide group and the tetrahydroquinoline ring (15), hampered the proper accommodation of the compound at the receptor binding site, leading to reduced potency. Insertion of a hydrophilic acetamide substituent on the nitrogen atom (81) was even more detrimental, abolishing any binding to the MT<sub>1</sub> receptor and severely reducing the affinity for the MT<sub>2</sub> receptor.

To evaluate the conformational equilibria of the most interesting *N*-benzyltetrahydroquinoline derivatives, molecular dynamics (MD) simulations were set up for compound 8e, the analogue of compound 8d having a shorter acetyl side chain instead of a propionyl and similar binding affinity and intrinsic activity. A 50 ns long well-tempered metadynamics simulation of compound 8e solvated into a water box was performed, setting as collective variables the dihedral angles  $\tau_1$  and  $\tau_2$  (Figure 3a), which describe the arrangement of the amide side chain and of the benzyl substituent, respectively. Compound 8e has a stereogenic center and the free-energy profiles here presented refer to the *R* enantiomer (the same results, with opposite values of dihedral angles, can be obtained for the *S* enantiomer). The well-tempered metadynamics simulation reached convergence after 20 ns (see Experimental Section for details). According to the free-energy surface (FES) depicted in Figure 3b, the amide side chain ( $\tau_1$ ) can assume an axial ( $\sim -50^\circ$ ) or an equatorial arrangement ( $\sim 50^\circ$ ), with lower energies associated with the former one. The benzyl substituent has a different conformational freedom depending on the arrangement of the amide side chain. With the amide side chain in equatorial arrangement, the benzyl substituent adopts two prevalent conformations, above ( $\tau_2 \sim -50^\circ$ ) or beneath ( $\sim 100^\circ$ ) the plane defined by the tetrahydroquinoline ring. On the contrary, it has higher conformational freedom with the amide side chain in axial arrangement. Indeed, the benzyl group explores almost all the possible conformations with similar free-energy contents, with the exception of  $\tau_2 \sim 0^\circ$ ,

a saddle point in the FES corresponding to an eclipsed arrangement of the benzyl substituent and the tetrahydroquinoline ring. In fact, the minimum free-energy conformation of compound 8e has an axial amide side chain with the benzyl substituent oriented toward the opposite side of the tetrahydroquinoline ring (Figure 3c). Consistent results in terms of conformational equilibrium were obtained with a more time-consuming plain MD simulation. When the trajectory of solvated compound 8e was simulated for 1  $\mu$ s, the amide side chain almost exclusively adopted an axial arrangement ( $\tau_1 \sim -50^\circ$ ), with only about 4.5% of equatorial conformations. The benzyl substituent spent most of the time perpendicular to the plane of the tetrahydroquinoline ring ( $\tau_2 \approx -70^\circ$ , 55% of sampled conformations), with higher conformational freedom associated with the axial side chain arrangement than to the equatorial one (Supporting Information Figure 1). Thus, a 50 ns long metadynamics simulation gave the same result as a 1  $\mu$ s simulation of plain MD, which proposes the first as a convenient approach to explore conformational equilibria of bioactive compounds.

To evaluate the reliability of the metadynamics simulation, we also performed a well-tempered metadynamics of compound 8e in methanol and we compared the results with the information obtained from NMR experiments in CD<sub>3</sub>OD. The FES obtained after 20 ns of metadynamics simulation in methanol is qualitatively the same as that obtained with water solvation (Supporting Information Figure S2). Analysis of 1D and 2D NMR data for compound 8e in CD<sub>3</sub>OD revealed a high prevalence of half-chair conformation for the tetrahydroquinoline ring wherein the C2 amide side chain is axially arranged (Table 2 and Supporting Information Figure S3; detailed description of <sup>1</sup>H spectrum is reported in the Supporting Information). <sup>1</sup>H–<sup>1</sup>H vicinal coupling constant analysis showed *J* values = 3.0 and 4.8 for H<sub>2</sub> with H<sub>3A</sub> and H<sub>3B</sub>, respectively, indicative of a gauche arrangement of H<sub>2</sub> with both H<sub>3</sub> protons and consistent with the ring conformation depicted in Figure 3c. Additionally, *J* values for protons H<sub>3</sub> and H<sub>4</sub> are consistent with an antiperiplanar arrangement of H<sub>4A</sub> and H<sub>3B</sub> (*J*<sub>3B,4A</sub> = 13.2, Table 2). 2D NOESY data of compound 8e (Supporting Information Figure S4) are also consistent with the prevalence of conformations with axial amide side chain. In fact, strong NOE contacts of the same intensities were recorded for H<sub>3A</sub> and H<sub>3B</sub> with both H<sub>2</sub> and H<sub>4B</sub>: similar distances among these couples of protons are only consistent with equatorial arrangements of H<sub>2</sub> and H<sub>4B</sub>. NMR data also supported the conformational equilibrium simulated for the benzyl group and



Table 1. Binding Affinity and Intrinsic Activity of Newly Synthesized Tetrahydroquinoline Derivatives for Human MT<sub>1</sub> and MT<sub>2</sub> Melatonin Receptors<sup>a</sup>






												
6a, 6d, 6h-i, 6l-n, 8a-l, 11				6j-k, 13			7			15		
compd <sup>b</sup>	R <sup>1</sup>	R <sup>2</sup>	R	MT <sub>1</sub>			MT <sub>2</sub>					
				K <sub>i</sub> (nM)	E <sub>max</sub> (%)	EC <sub>50</sub> (nM)	K <sub>i</sub> (nM)	E <sub>max</sub> (%)	EC <sub>50</sub> (nM)			
1 <sup>c</sup>				0.23	123 ± 13	1.7	0.52	76 ± 6	0.4			
melatonin				[0.21;0.26]		[1.1;2.5]	[0.4;0.58]		[0.3;0.6]			
6a	Et	H	5-OMe	57	70 ± 5	906	21	98 ± 9	165			
				[51;62]		[567;1450]	[20;25]		[81;333]			
6d	Et	H	H	13	37 ± 1	242	2.2	86 ± 2	27			
				[9;16]		[168;349]	[2;2.3]		[22;35]			
6h	NHEt	H	5-OMe	480	nd	nd	114	nd	nd			
				[423;502]			[98;132]					
6i	NHEt	H	H	115	30 ± 3	2420	17	80 ± 0	356			
				[98;123]		[1978;2736]	[16;18]		[258;492]			
6j		H	5-OMe	>1000	nd	nd	>1000	nd				
6k		H	H	305	35 ± 2	2660	90	72 ± 2	1430			
				[274;382]		[1270;5580]	[67;111]		[1350;1530]			
6l	NHEt	Me	5-OMe	5	92 ± 12	160	1.4	105 ± 3	10			
				[4;5.5]		[81;317]	[1.3;1.5]		[9;10]			
6m	NHEt	Me	H	5.3	69 ± 8	110	3.4	97 ± 1	6.2			
				[4.8;5.7]		[52;235]	[2.8;3.7]		[4.7;8.2]			
6n	NHEt	Bn	5-OMe	132	44 ± 4	393	2.9	107 ± 1	13			
				[127;154]		[375;412]	[2.5;3.1]		[11;15]			
7				>10000	nd	nd	4450	nd	nd			
							[2480;7990]					
8a	Et	Bn	5-OMe	17	79 ± 7.5	177	0.001	111 ± 3.5	0.9			
UCM1014				[15;86]		[92;340]	[0.0002;0.005]		[0.7;1]			
8b	Et	Bn	6-OMe	186	nd	nd	1.5	75 ± 7	4.6			
				[106;324]			[0.8;2.9]		[3.4;6.4]			
8c	Et	Bn	7-OMe	214	nd	nd	26	42 ± 5	25			
				[111;414]			[10;66]		[22;29]			
8d	Et	Bn	H	37	42 ± 10	36	0.09	73 ± 2	0.4			
				[19;72]		[35;37]	[0.04;0.2]		[0.4;0.5]			
8e	Me	Bn	H	45	35 ± 2	31	0.04	60 ± 2	0.4			
				[40;50]		[20;49]	[0.02;0.1]		[0.3;0.6]			
(-)-8e	Me	Bn	H	45	52 ± 4	192	0.1	80 ± 8	1.9			
				[18;110]		[106;348]	[0.04;0.3]		[1.5;2.4]			
(+)-8e	Me	Bn	H	122	nd	nd	6.2	60 ± 15	19			
				[112;132]			[5.2;7.2]		[8.7;40]			
8f	cPr	Bn	H	291	nd	nd	0.2	38 ± 4	0.3			
				[168;505]			[0.2;0.3]		[0.1;0.8]			
8g	cBu	Bn	H	633	nd	nd	6.2	<15	nd			
				[201;2000]			[5.6;6.8]					
8h	Et	Me	5-OMe	0.03	112 ± 12	1.7	0.5	122 ± 9	0.5			
				[0.01;0.05]		[1.4;2]	[0.3;0.9]		[0.5;0.6]			
8i	Et	Me	H	0.7	69 ± 3	0.9	0.2	122 ± 11	0.6			
				[0.6;0.8]		[0.7;1.2]	[0.2;0.3]		[0.5;0.8]			
8j	Me	CH <sub>2</sub> -CH <sub>2</sub> -Ph	H	171	nd	nd	3[1.5;4.7]	<15	nd			
				[81;361]								
8k	Me	nPr	H	5.8	39 ± 5	2	0.1	58 ± 0.5	0.2			
				[4.1;8.2]		[1;6]	[0.06;0.2]		[0.07;0.4]			
8l	Et	CH <sub>2</sub> CONHMe	H	>10000	nd	nd	385	nd	nd			
							[312;423]					
11	Et	Ph	H	1.6	69 ± 12	6.2	0.06	90 ± 0.5	0.5			
				[0.6;4.3]		[6.1;6.2]	[0.03;0.1]		[0.3;0.7]			
13		Me	H	22	76 ± 4	809	15	73 ± 1	66			

Table 1. continued


compd <sup>b</sup>	R <sup>1</sup>	R <sup>2</sup>	R	MT <sub>1</sub>			MT <sub>2</sub>		
				K <sub>i</sub> (nM)	E <sub>max</sub> (%)	EC <sub>50</sub> (nM)	K <sub>i</sub> (nM)	E <sub>max</sub> (%)	EC <sub>50</sub> (nM)
15				[20;25]	nd	[623;1050]	[11;18]	59 ± 4	[51;85]
				326		nd	1.6		4.7
				[190;554]			[0.7;3.4]		[3.2;6.9]

<sup>a</sup>K<sub>i</sub> (nM) values are geometric mean values (with 95% confidence limits shown in brackets) of at least two separate experiments performed in duplicate. E<sub>max</sub> values are arithmetic mean ± SEM. nd: non determined. <sup>b</sup>Compounds were tested as racemates, with the exception of compounds 7, (+)-8e, and (–)-8e. <sup>c</sup>Data for melatonin were taken from Landagaray E. et al.<sup>41</sup>



**Figure 3.** (a) Representation of  $\tau_1$  ( $N_1-C_2-C_3-C_4$ , pink bonds),  $\tau_2$  ( $C_{8a}-N_1-C_{bn}-C_{ar}$ , green bonds) and  $\tau_3$  ( $N_1-C_2-C_\alpha-N_{am}$ ) dihedral angles. (b) Free energy surface for compound 8e obtained after 20 ns of well-tempered metadynamics simulation. (c) Representation of one of the conformations of compound 8e corresponding to the free-energy minimum ( $\tau_1 = -57.7^\circ$ ,  $\tau_2 = -71.1^\circ$ ).

**Table 2.** Selected Vicinal Coupling Constants Values Observed by NMR Spectroscopy (600 or 400 MHz, CD<sub>3</sub>OD, 25 °C) for Compounds 6d, 8e, and 8i (R Enantiomers Depicted)



protons <sup>a</sup>	8e J (Hz)	8i (R <sup>1</sup> = Me) J (Hz)	6d (R <sup>1</sup> = H) J (Hz)
<sup>3</sup> J <sub>2,3A</sub>	3.0 <sup>b</sup>	3.2	9.2
<sup>3</sup> J <sub>2,3B</sub>	4.8 <sup>b</sup>	4.4	3.2
<sup>3</sup> J <sub>3A,4B</sub>	3.6	3.2	9.2
<sup>3</sup> J <sub>3B,4B</sub>	3.6	4.8	5.4
<sup>3</sup> J <sub>3B,4A</sub>	13.2	12.8	5.6
<sup>3</sup> J <sub>3A,4A</sub>	5.4	5.7	6.0
<sup>3</sup> J <sub>2,10A</sub>	4.8 <sup>b</sup>	5.0	5.2
<sup>3</sup> J <sub>2,10B</sub>	9.0 <sup>b</sup>	9.0	6.4

<sup>a</sup>Letter A denotes protons under the plane defined by the tetrahydroquinoline ring in the orientation depicted in the table, letter B above the plane.


<sup>b</sup>Reported J values are those obtained from NMR signals of protons H<sub>3A</sub>, H<sub>3B</sub>, H<sub>10A</sub>, and H<sub>10B</sub>, as the signal of proton H<sub>2</sub> is not well resolved.

the amide side chain. The presence of NOE contacts for the two methylene hydrogens H<sub>9</sub> with protons H<sub>2</sub>, H<sub>8</sub>, and H<sub>10A</sub> suggests that the benzyl substituent is rather free to rotate and can assume different conformations. NOE signals observed for

H<sub>9</sub> protons with H<sub>10A</sub>, but not with H<sub>10B</sub>, as well as strong NOE contacts between H<sub>4A</sub> and H<sub>10B</sub>, but not with H<sub>10A</sub>, reveal limited conformational freedom of the amide side chain. This is further supported by the two different values of J recorded for

H<sub>2</sub> with H<sub>10A</sub> and H<sub>10B</sub>, with H<sub>10A</sub> spending most of the time in gauche to H<sub>2</sub>, closer to the benzyl protons H<sub>9</sub>, while H<sub>10B</sub> was principally anti to H<sub>2</sub>, pointing toward H<sub>4a</sub>. This preferred arrangement of the side chain, corresponding to  $\tau_3 \sim 180^\circ$ , was captured by the plain MD simulation (Supporting Information Figure S5). The reliability of the results obtained from MD simulations, tested on these tetrahydroquinolines as well as on tetralin<sup>26</sup> derivatives, supports the application of this technique to estimate the conformational abundance of compounds in solution to drive the design and synthesis of new compounds. Moreover, metadynamics simulations gave an additional advantage over plain MD in terms of computational speed.

When the amide side chain is in axial arrangement, only one of the two enantiomers of **8e** can fit the pharmacophore model for melatonergic ligands and reproduce the putative bioactive conformation of melatonin.<sup>17</sup> Thus, the conformational equilibrium described above implies that this compound would show significant stereoselectivity, which was confirmed by separation of the enantiomers on a chiral chromatographic column and by individual testing at the MT<sub>1</sub> and MT<sub>2</sub> receptors. The eutomer (–)-**8e** showed about 60-fold higher MT<sub>2</sub> binding affinity than (+)-**8e** and greater potency in activating the MT<sub>2</sub> receptor. As shown in Figure 4, the enantiomer (*R*)-**8e** perfectly fits the bioactive conformation of melatonin, which suggests it should correspond to the eutomer (–)-**8e**.



**Figure 4.** Superposition of melatonin (yellow carbons) and two representative conformations of compound **8e** with the benzyl group in an out-of-plane arrangement ( $\tau_2 = -71.1^\circ$ , orange carbons) and in an in-plane arrangement ( $\tau_2 = -172.7^\circ$ , green carbons).

The substituent at the tetrahydroquinoline nitrogen affects the conformational equilibrium of these compounds, as it promotes the axial arrangement of the amide side chain, with important consequences on the binding profile and SARs. This is supported by 1D and 2D NMR experiments performed on the *N*-methyl (**8i**) and the *N*-unsubstituted (**6d**) derivatives (Table 2 and Supporting Information Figures S6–S8). Vicinal coupling constants as well as NOE contacts recorded for compound **8i** highlighted the same preferential axial arrangement of the amide side chain seen for the benzyl derivative **8e**. On the other hand, in the case of **6d**, experimental *J* values can be interpreted by assuming an equilibrium between two half-

chair conformations of the tetrahydroquinoline ring, one with equatorial amide side chain and the other with axial amide, inverting rapidly on the NMR time scale. In particular the *J*<sub>2–3A</sub> value  $\approx 9$  Hz must be considered as the average *J* value of both arrangements. A well-tempered metadynamics simulation performed on compound **6d** provided results consistent with these NMR data and estimated almost equal free-energy content for the axial and the equatorial arrangements of the amide side chain (Supporting Information Figure S9). Therefore, while both the *N*-methyl and the *N*-benzyl substituents promote the conformations which fit the pharmacophore model, the lower potency observed for the *N*-unsubstituted derivative **6d** might be due, at least in part, to the presence of the equatorial species in solution. According to MD simulations and NMR experiments, the benzyl group of compound **8e** can alternatively be arranged perpendicular to the tetrahydroquinoline ring, with an out-of-plane hindrance typical of MT<sub>2</sub>-selective antagonists, or coplanar with the tetrahydroquinoline, occupying a region of space where substituents of melatonin receptor agonists are usually present, like the phenyl ring of 2-phenylmelatonin (Figure 4). We speculate that this conformational flexibility could be responsible for the MT<sub>2</sub> selectivity of compound **8e** and also for the residual intrinsic activity. Indeed, selectivity for the MT<sub>2</sub> receptor should be guaranteed by the bulky benzyl group that could hardly fit the MT<sub>1</sub> binding site, which is supposed to have reduced tolerance toward out-of-plane space occupancy. On the other hand, at the MT<sub>2</sub> receptor, compound **8e** could also assume an in-plane conformation of the benzyl group, leading to receptor activation. Of course, this behavior is likely to involve some conformational flexibility of the receptor.

The effect of substituents on the nitrogen atom was further analyzed. Lengthening of the benzyl substituent into a phenethyl one (**8j**) led to a significant drop of binding affinity at both receptor subtypes, suggestive of some steric hindrance at the receptor binding site. The smaller *N*-propyl derivative **8k** showed significantly higher MT<sub>1</sub> and MT<sub>2</sub> binding affinity.

A well-known SAR feature of melatonin receptor ligands is related to the methoxy group, which increases both binding affinity and intrinsic activity when it can mimic the same group of melatonin. According to the superposition model represented in Figure 4, the best position for the methoxy group should be position 5 of the tetrahydroquinoline scaffold. To test this hypothesis, we synthesized three isomers having the methoxy group in position 5 (**8a**), 6 (**8b**), or 7 (**8c**), maintaining the benzyl substituent at the nitrogen atom. For these compounds, we selected the propionyl group at side chain due to the slightly higher intrinsic activity at MT<sub>2</sub> receptor for **8d**, compared to the acetyl derivative **8e**. While 6- and 7-methoxy groups were detrimental for receptor recognition, the 5-methoxy group led to increased MT<sub>1</sub> and MT<sub>2</sub> binding affinities. The positive effect of the 5-methoxy group was particularly relevant at the MT<sub>2</sub> receptor, leading to compound **8a** with picomolar binding affinity, more than 10000-fold MT<sub>2</sub>-selectivity, and a full agonist behavior at the MT<sub>2</sub> receptor. This compound is the most selective MT<sub>2</sub> full agonist reported to date.<sup>27</sup> We further tested the efficacy of the 5-methoxy group on the tetrahydroquinoline scaffold by modifying the substituent at the nitrogen atom. Compound **8h**, having 5-methoxy and *N*-methyl substituent, has higher MT<sub>1</sub> binding affinity than the desmethoxy analogue **8i**, behaving as a full agonist at both receptor subtypes. Unexpectedly, insertion of the 5-methoxy group on the *N*-unsubstituted tetrahydroquino-

line **6d** led to compound **6a** with decreased binding affinity and intrinsic activity. This peculiar behavior might be related to the presence of the polar hydrogen which might favor a different accommodation at the receptor binding site. SARs typical of melatonin receptor ligands were further confirmed by compounds with different acylating groups. Replacement of the ethyl group on the amide side chain by a cyclopropyl (**8f**) or a cyclobutyl (**8g**) ring led to the expected drop in binding affinity and intrinsic activity. As a confirmation of the importance of the tetrahydroquinoline scaffold to reproduce the active conformation of melatonin, we synthesized the fully unsaturated quinoline **7**, which was devoid of binding affinity.

We also explored different side chains which could represent an alternative to the amide one, focusing on ethylurea and thioethylurea derivatives. The ethylurea side chain, with either a methyl (**6m**) or a hydrogen atom (**6i**) at the tetrahydroquinoline nitrogen, led to significant decreases of binding affinity, as it had been observed for agomelatine<sup>28</sup> and 1,6-dihydro-2H-indeno[5,4-*b*]furan derivatives.<sup>29</sup> Insertion of a 5-methoxy group on the tetrahydroquinoline scaffold (**6l**, **6h**, and **6n**) did not produce the expected increase of binding affinity. The three thioethylurea derivatives **13**, **6k**, and **6j** were even less potent than the corresponding urea derivatives **6m**, **6i**, and **6l**, respectively.

## CONCLUSIONS

Starting from molecular superpositions on previously developed pharmacophore models, the scaffold of *N*-anilinoethylamide melatonin receptor ligands, which had provided potent and MT<sub>2</sub>-selective antagonists or partial agonists, was partially constrained to a 2-acylaminomethyl-tetrahydroquinoline nucleus. This nucleus proved to be an excellent new scaffold to develop new melatonergic selective agonists, and the benzyl substituent on the tetrahydroquinoline nitrogen favored the proper arrangement of the amide side chain, mimicking the active conformation of melatonin.

Superposition models, supported by extended conformational analysis by MD simulations and NMR experiments, allowed prediction of the suitable position for a methoxy group on the tetrahydroquinoline ring, leading to the benzyl derivative **8a** (UCM1014), an extremely potent and selective full agonist at MT<sub>2</sub> receptor.

As a final remark, metadynamics simulations proved to give reliable results on the free-energy profile and conformational preferences of these compounds at much lower computational cost than classical plain molecular dynamics.

## EXPERIMENTAL SECTION

**General Procedures.** Melting points were determined on a Buchi B-540 capillary melting point apparatus and are uncorrected. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on a Bruker AVANCE 200 or 400 instrument or on a Varian INOVA 600 MHz spectrometer, using CDCl<sub>3</sub> as solvent unless stated otherwise. Chemical shifts ( $\delta$  scale) are reported in parts per million (ppm) relative to the central peak of the solvent. Coupling constants (*J*) are given in hertz (Hz). EI MS spectra (70 eV) were taken on a Fisons Trio 1000 instrument; only molecular ions (*M*<sup>+</sup>) and base peaks are given. ESI MS spectra were taken on a Waters Micromass ZQ instrument; only molecular ions (*M* + 1)<sup>+</sup> are given. The purity of tested compounds, determined by high pressure liquid chromatography (HPLC), was greater than 95% (Supporting Information Table S1). These analyses were performed on a Waters HPLC/UV/MS system (separation module Alliance HT2795, photo diode array detector 2996, mass detector Micromass ZQ; software, MassLynx 4.1).

Column chromatography purifications were performed under "flash" conditions using Merck 230–400 mesh silica gel. Analytical thin-layer chromatography (TLC) was carried out on Merck silica gel 60 F<sub>254</sub> plates. 2-Quinolincarbonitrile (**4d**) was purchased from commercial suppliers and was used without further purification.

**Synthesis of 5-, 6-, and 7-Methoxyquinoline-2-carbonitriles (4a–c).** CH<sub>3</sub>I (0.15 mL, 2.4 mmol) and K<sub>2</sub>CO<sub>3</sub> (0.412 g, 3 mmol) were added to a solution of the suitable hydroxy-2-cyanoquinoline derivative **3a–c** (0.17 g, 1 mmol) in acetone (8 mL), and the resulting mixture was stirred at room temperature for 15 h. The solvent was evaporated, and the residue was taken up with water and extracted (3×) with EtOAc. The organic phases were combined, dried (Na<sub>2</sub>SO<sub>4</sub>), and evaporated to afford a crude product which was purified by flash chromatography over silica gel (cyclohexane/EtOAc 7:3 as eluent) and crystallization.

**5-Methoxyquinoline-2-carbonitrile (4a).** White solid, mp 113–4 °C (EtOAc–petroleum ether); 95% yield. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>)  $\delta$  4.05 (s, 3H), 7.00 (dd, 1H, *J*<sub>1</sub> = *J*<sub>2</sub> = 4.5), 7.69 (d, 1H, *J* = 8.5), 7.74–7.77 (m, 2H), 8.73 (d, 1H, *J* = 8.5 Hz). ESI MS (*m/z*): 185 (*M* + H)<sup>+</sup>.

**6-Methoxyquinoline-2-carbonitrile (4b).** White solid, mp 176–7 °C (EtOH–H<sub>2</sub>O); 88% yield. Physicochemical data were in agreement to those previously reported.<sup>30</sup>

**7-Methoxyquinoline-2-carbonitrile (4c).** White solid, mp 187–8 °C (EtOAc–petroleum ether); 74% yield. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>)  $\delta$  3.99 (s, 3H), 7.36 (dd, 1H, *J* = 2.5 and 9.0 Hz), 7.46 (d, 1H, *J* = 2.5 Hz), 7.60 (d, 1H, *J* = 8.5 Hz), 7.78 (d, 1H, *J* = 9.0 Hz), 8.22 (d, 1H, *J* = 8.5 Hz). ESI MS (*m/z*): 185 (*M* + H)<sup>+</sup>.

**Synthesis of *N*-[(1,2,3,4-Tetrahydroquinolin-2-yl)methyl]alkanamides (6a–g).** A solution of the suitable quinoline-2-carbonitrile **4a–d** (1 mmol) in THF (5 mL) and 2 M NH<sub>3</sub> in EtOH (0.6 mL) was hydrogenated over Raney nickel (4 atm) for 16 h at 60 °C. The catalyst was filtered on Celite, the filtrate was concentrated in vacuo, and the residue partitioned between EtOAc and water. The organic phase was washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and evaporated under reduced pressure to give the corresponding crude oily methanamine (**5a–d**), which was used without any further purification.

Et<sub>3</sub>N (0.14 mL) and the suitable anhydride or acyl chloride (1 mmol) were added to a cold solution of the appropriate above crude methanamine **5a–d** in THF (6 mL), and the resulting mixture was stirred at room temperature for 1 h. The solvent was evaporated under reduced pressure, the residue was taken up in EtOAc and washed with a saturated aqueous solution of NaHCO<sub>3</sub> and with brine. After drying over Na<sub>2</sub>SO<sub>4</sub>, the solvent was removed by distillation in vacuo to give a crude product that was purified by flash chromatography.

***N*-[(5-Methoxy-1,2,3,4-tetrahydroquinolin-2-yl)methyl]propionamide (6a).** Flash chromatography: silica gel, EtOAc as eluent. White solid, mp 108–9 °C (Et<sub>2</sub>O–petroleum ether); 54% yield. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>)  $\delta$  1.17 (t, 3H, *J* = 7.5 Hz), 1.61–1.75 (m, 1H), 1.87–1.96 (m, 1H), 2.25 (q, 2H, *J* = 7.5 Hz), 2.48–2.65 (m, 1H), 2.75–2.88 (m, 1H), 3.37–3.45 (m, 3H), 3.79 (s, 3H), 4.01 (br s, 1H), 5.76 (br s, 1H), 6.20–6.24 (m, 2H), 6.96 (dd, 1H, *J*<sub>1</sub> = *J*<sub>2</sub> = 8.0 Hz). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>)  $\delta$  174.6, 157.8, 144.5, 126.9, 109.8, 108.1, 99.9, 55.3, 50.9, 44.1, 29.7, 25.0, 19.7, 9.9. ESI MS (*m/z*): 249 (*M* + H)<sup>+</sup>.

***N*-[(6-Methoxy-1,2,3,4-tetrahydroquinolin-2-yl)methyl]propionamide (6b).** Flash chromatography: silica gel, EtOAc as eluent. Oil; 50% yield. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>)  $\delta$  1.18 (t, 3H, *J* = 7.5 Hz), 1.65–1.76 (m, 1H), 1.84–1.95 (m, 1H), 2.25 (q, 2H, *J* = 7.5 Hz), 2.73–2.86 (m, 2H), 3.38–3.49 (m, 3H), 3.74 (s, 3H), 5.79 (brs, 1H), 6.48–6.65 (m, 3H). EI MS (*m/z*): 248 (*M*<sup>+</sup>), 162 (100).

***N*-[(7-Methoxy-1,2,3,4-tetrahydroquinolin-2-yl)methyl]propionamide (6c).** Flash chromatography: silica gel, EtOAc/cyclohexane 9:1 as eluent. Amorphous solid; 47% yield. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>)  $\delta$  1.17 (t, 3H, *J* = 7.5 Hz), 1.66–1.77 (m, 1H), 1.83–1.95 (m, 1H), 2.26 (q, 2H, *J* = 7.5 Hz), 2.72–2.79 (m, 2H), 3.42–3.49 (m, 3H), 3.74 (s, 3H), 5.91 (br s, 1H), 6.17 (d, 1H, *J* = 2.5 Hz), 6.28 (dd, 1H, *J* = 2.5 and 8.0 Hz), 6.89 (d, 1H, *J* = 8.0 Hz). ESI MS (*m/z*): 249 (*M* + H)<sup>+</sup>.



*N*-[(1,2,3,4-Tetrahydroquinolin-2-yl)methyl]propionamide (**6d**). Flash chromatography: silica gel, EtOAc/cyclohexane 7:3 as eluent. Beige solid, mp 67–8 °C (Et<sub>2</sub>O–petroleum ether); 63% yield. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 1.16 (t, 3H, *J* = 7.5 Hz), 1.65 (dddd, 1H, *J*<sub>1</sub> = 6.0, *J*<sub>2</sub> ≈ *J*<sub>3</sub> = 9.0 and *J*<sub>4</sub> = 13.0 Hz, H<sub>3B</sub>), 1.94 (dddd, 1H, *J*<sub>1</sub> = 3.0, *J*<sub>2</sub> ≈ *J*<sub>3</sub> = 5.5 and *J*<sub>4</sub> = 13.5 Hz, H<sub>3A</sub>), 2.25 (q, 2H, *J* = 7.5 Hz), 2.73 (ddd, 1H, *J* = 5.5, 6.0, and 16.0 Hz, H<sub>4B</sub>), 2.79 (ddd, 1H, *J* = 5.5, 9.0, and 16.0 Hz, H<sub>4A</sub>), 3.27 (dd, 1H, *J* = 6.5 and 13.0 Hz, H<sub>10B</sub>), 3.31 (dd, 1H, *J* = 5.0 and 13.0 Hz, H<sub>10A</sub>), 3.37 (dddd, 1H, *J*<sub>1</sub> = 3.0, *J*<sub>2</sub> = 5.0, *J*<sub>3</sub> = 6.5 and *J*<sub>4</sub> = 9.0 Hz, H<sub>2</sub>), 6.52–6.56 (m, 2H, arom), 6.88–6.90 (m, 2H, arom). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>) δ 174.7, 144.0, 129.2, 126.9, 121.1, 117.5, 114.5, 51.2, 44.4, 29.7, 25.9, 25.4, 9.9. ESI MS (*m/z*): 219 (*M* + H)<sup>+</sup>.

<sup>1</sup>H NMR spectrum of compound **6d** is depicted in Supporting Information Figure S8.

*N*-[(1,2,3,4-Tetrahydroquinolin-2-yl)methyl]acetamide (**6e**). Flash chromatography: silica gel, EtOAc/MeOH 96:4 as eluent. Oil; 73% yield. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 1.58–1.77 (m, 1H), 1.84–1.97 (m, 1H), 2.01 (s, 3H), 2.68–2.86 (m, 2H), 3.38–3.50 (m, 3H), 6.49 (d, 1H, *J* = 8.0 Hz), 6.60 (dd, 1H, *J*<sub>1</sub> = *J*<sub>2</sub> = 7.5 Hz), 6.80 (br t, 1H), 6.93–7.04 (m, 2H). EI MS (*m/z*): 204 (*M*<sup>+</sup>), 132 (100).

*N*-[(1,2,3,4-Tetrahydroquinolin-2-yl)methyl]-cyclopropanecarboxamide (**6f**). Flash chromatography: silica gel, EtOAc/cyclohexane 8:2 as eluent. Oil; 73% yield. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 0.70–0.80 (m, 2H), 0.95–1.02 (m, 2H), 1.30–1.42 (m, 1H), 1.63–1.97 (m, 2H), 2.65–2.85 (m, 2H), 3.38–3.54 (m, 3H), 5.97 (br s, 1H), 6.52 (d, 1H, *J* = 8.5 Hz), 6.61 (dd, 1H, *J*<sub>1</sub> = *J*<sub>2</sub> = 7.5 Hz), 6.94–7.02 (m, 2H). ESI MS (*m/z*): 231 (*M* + H)<sup>+</sup>.

*N*-[(1,2,3,4-Tetrahydroquinolin-2-yl)methyl]-cyclobutanecarboxamide (**6g**). Flash chromatography: silica gel, EtOAc/cyclohexane 7:3 as eluent. Oil; 34% yield. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 1.60–2.38 (m, 8H), 2.66–2.90 (m, 2H), 2.93–3.10 (m, 1H), 3.37–3.53 (m, 3H), 5.68 (br s, 1H), 6.52 (d, 1H, *J* = 8.0 Hz), 6.63 (dd, 1H, *J*<sub>1</sub> = *J*<sub>2</sub> = 7.5 Hz), 6.94–7.02 (m, 2H). ESI MS (*m/z*): 245 (*M* + H)<sup>+</sup>.

**General Procedure for the Synthesis of (1,2,3,4-Tetrahydroquinolin-2-yl)ureido Derivatives (6h–k).** The suitable ethyl isocyanate (1 mmol) was added to a cold solution of the appropriate above crude (1,2,3,4-tetrahydroquinolin-2-yl)methanamine (**5a** or **5d**) (from 1 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (6 mL), and the resulting mixture was stirred at room temperature for 30 min. The solvent was evaporated under reduced pressure, and the residue was purified by flash chromatography.

*1-Ethyl-3-[(5-methoxy-1,2,3,4-tetrahydroquinolin-2-yl)methyl]urea* (**6h**). Flash chromatography: silica gel, EtOAc as eluent. White solid, mp 131–2 °C (EtOAc–petroleum ether); 60% yield. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 1.14 (t, 3H, *J* = 7.2 Hz), 1.58–1.74 (m, 1H), 1.85–1.97 (m, 1H), 2.47–2.64 (m, 1H), 2.74–2.86 (m, 1H), 3.15–3.43 (m, 5H), 3.79 (s, 3H), 4.15 (br s, 1H), 4.37 (br s, 1H), 4.63 (br s, 1H), 6.22 (app t, 2H), 6.95 (dd, 1H, *J*<sub>1</sub> = *J*<sub>2</sub> = 8.0 Hz). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>) δ 159.0, 157.8, 144.9, 126.9, 109.7, 108.0, 99.6, 55.2, 51.3, 45.4, 33.7, 25.1, 19.7, 15.4. EI MS (*m/z*): 263 (*M*<sup>+</sup>), 162 (100).

*1-Ethyl-3-[(1,2,3,4-tetrahydroquinolin-2-yl)methyl]urea* (**6i**). Flash chromatography: silica gel, EtOAc as eluent. White solid, mp 86–7 °C (Et<sub>2</sub>O); 49% yield. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 200 MHz) δ 1.15 (t, 3H, *J* = 7.2 Hz), 1.60–1.80 (m, 1H), 1.85–1.95 (m, 1H), 2.72–2.86 (m, 2H), 3.16–3.36 (m, 4H), 3.41–3.48 (m, 1H), 4.13 (br s, 1H), 4.30 (br s, 1H), 4.57 (br s, 1H), 6.52 (d, 1H, *J* = 8.0 Hz), 6.63 (dd, 1H, *J*<sub>1</sub> = *J*<sub>2</sub> = 7.0 Hz), 6.95–7.02 (m, 2H). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>) δ 158.9, 143.8, 129.2, 126.8, 121.4, 117.6, 114.6, 51.8, 45.6, 35.3, 25.9, 25.4, 15.4. ESI MS (*m/z*): 234 (*M* + H)<sup>+</sup>.

*1-Ethyl-3-[(5-methoxy-1,2,3,4-tetrahydroquinolin-2-yl)methyl]thiourea* (**6j**). Flash chromatography: silica gel, cyclohexane–EtOAc 8:2 as eluent. White solid, mp 115–6 °C (EtOAc–petroleum ether); 63% yield. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 1.22 (t, 3H, *J* = 7.2 Hz), 1.63–1.81 (m, 1H), 1.86–1.98 (m, 1H), 2.58–2.85 (m, 2H), 3.32–3.45 (m, 2H), 3.54–3.70 (m, 3H), 3.80 (s, 3H), 4.04 (br s, 1H), 6.01 (br s, 2H), 6.22 (d, 1H, *J* = 8.0 Hz), 6.28 (d, 1H, *J* = 8.0 Hz), 6.98 (dd, 1H, *J*<sub>1</sub> = *J*<sub>2</sub> = 8.0 Hz). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>) δ 182.3, 157.8,

144.1, 127.0, 110.1, 108.4, 100.3, 55.3, 50.4, 49.2, 39.1, 24.9, 19.3, 14.1. EI MS (*m/z*): 279 (*M*<sup>+</sup>), 162 (100).

*1-Ethyl-3-[(1,2,3,4-tetrahydroquinolin-2-yl)methyl]thiourea* (**6k**). Flash chromatography: silica gel, cyclohexane/EtOAc 7:3 as eluent. White solid, mp 107–8 °C (Et<sub>2</sub>O–petroleum ether); 65% yield. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 1.23 (t, 3H, *J* = 7.2 Hz), 1.66–1.86 (m, 1H), 1.91–2.01 (m, 1H), 2.70–2.93 (m, 2H), 3.28–3.51 (m, 2H), 3.52–3.69 (m, 3H), 4.07 (br s, 1H), 6.10 (br s, 2H), 6.56 (d, 1H, *J* = 8.0 Hz), 6.69 (dd, 1H, *J*<sub>1</sub> = *J*<sub>2</sub> = 8.0 Hz), 6.98–7.05 (m, 2H). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>) δ 182.4, 143.3, 129.3, 127.0, 121.5, 118.2, 115.1, 50.8, 49.5, 39.0, 25.6, 25.3, 14.1. ESI MS (*m/z*): 250 (*M* + H)<sup>+</sup>.

*1-Ethyl-3-[(5-methoxy-1-methyl-1,2,3,4-tetrahydroquinolin-2-yl)methyl]urea* (**6l**). A suspension of **6i** (1 mmol), NaHCO<sub>3</sub> (84 mg, 1 mmol) and methyl iodide (0.4 mL, 6.5 mmol) in dry methanol (11 mL) was heated at 50 °C for 24 h. After removing the solvent by distillation in vacuo, the residue was poured into water and extracted with EtOAc (4×), and the combined organic phases were washed with brine and dried (Na<sub>2</sub>SO<sub>4</sub>). The solvent was removed by distillation under reduced pressure, and the residue was purified by silica gel flash chromatography (cyclohexane/EtOAc 3:7 as eluent). White solid, mp 172–3 °C (EtOAc–petroleum ether); 77% yield. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 1.12 (t, 3H, *J* = 7.3 Hz), 1.78–2.00 (m, 2H), 2.38–2.56 (m, 1H), 2.77–2.90 (m, 1H), 3.03 (s, 3H), 3.08–3.47 (m, 5H), 3.80 (s, 3H), 4.25 (br s, 1H), 4.42 (br s, 1H), 6.28 (d, 1H, *J* = 8.0 Hz), 6.30 (d, 1H, *J* = 8.0 Hz), 7.07 (dd, 1H, *J*<sub>1</sub> = *J*<sub>2</sub> = 8.0 Hz). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>) δ 158.7, 157.1, 145.8, 127.0, 109.5, 104.7, 98.7, 57.9, 55.3, 41.4, 39.1, 35.2, 22.5, 17.0, 15.5. ESI MS (*m/z*): 278 (*M* + H)<sup>+</sup>.

*1-Ethyl-3-[(1-methyl-1,2,3,4-tetrahydroquinolin-2-yl)methyl]urea* (**6m**). This product was obtained starting from **6d** and using the above *N*<sup>1</sup>-methylation procedure described for compound **6l**. Flash chromatography: silica gel, EtOAc as eluent. White solid, mp 116–7 °C (EtOAc–petroleum ether); 77% yield. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 1.13 (t, 3H, *J* = 7.2 Hz), 1.83–1.95 (m, 2H), 2.71–2.79 (m, 2H), 3.02 (s, 3H), 3.12–3.27 (m, 3H), 3.34–3.49 (m, 2H), 4.24 (br s, 1H), 4.41 (br s, 1H), 6.58–6.66 (m, 2H), 6.99 (d, 1H, *J* = 7.0 Hz), 7.11 (dd, 1H, *J* = 7.0 and 8.0 Hz). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>) δ 158.3, 145.1, 128.6, 127.2, 122.2, 116.0, 111.1, 58.3, 42.1, 38.3, 35.3, 23.9, 23.5, 15.4. EI MS (*m/z*): 247 (*M*<sup>+</sup>), 146 (100).

*1-[(1-Benzyl-5-methoxy-1,2,3,4-tetrahydroquinolin-2-yl)methyl]-3-ethylurea* (**6n**). A solution of **6h** (0.263 g, 1 mmol), Et<sub>3</sub>N (0.27 mL), and benzyl bromide (0.19 mL, 1.6 mmol) in dry toluene (3 mL) was heated at reflux for 2 h. After cooling to room temperature, the reaction mixture was poured into water and extracted with EtOAc (3×); the combined organic phases were washed with brine and dried (Na<sub>2</sub>SO<sub>4</sub>). After removing the solvent by distillation under reduced pressure, the residue was purified by silica gel flash chromatography (EtOAc as eluent) and crystallization. White solid, mp 147–8 °C (acetone–petroleum ether); 88% yield. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 1.06 (t, 3H, *J* = 7.2 Hz), 1.83–2.01 (m, 2H), 2.44–2.62 (m, 1H), 2.82–3.13 (m, 3H), 3.22–3.28 (m, 2H), 3.45–3.57 (m, 1H), 3.82 (s, 3H), 3.96 (br s, 1H), 4.30 (br s, 1H), 4.53 (d, 1H, *J* = 17.0 Hz), 4.65 (d, 1H, *J* = 17.0 Hz), 6.28 (d, 1H, *J* = 8.0 Hz), 6.29 (d, 1H, *J* = 8.0 Hz), 6.99 (dd, 1H, *J*<sub>1</sub> = *J*<sub>2</sub> = 8.0 Hz), 7.24–7.37 (m, 5H). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>) δ 158.3, 157.3, 145.1, 139.6, 128.6, 126.9, 126.8, 126.7, 109.8, 106.3, 98.8, 57.4, 55.9, 55.3, 42.0, 35.2, 22.5, 17.1, 15.4. ESI MS (*m/z*): 354 (*M* + H)<sup>+</sup>.

*N*-[(5-Methoxyquinolin-2-yl)methyl]propionamide (**7**). A solution of **4a** (1 mmol) in 2N NH<sub>3</sub> in MeOH (8 mL) was hydrogenated over Raney nickel (3.5 atm) for 0.5 h at room temperature. The catalyst was filtered on Celite, the filtrate was concentrated in vacuo, and the residue was partitioned between EtOAc and water. The organic phase was washed with brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and evaporated under reduced pressure to give crude (5-methoxyquinolin-2-yl)methanamine, which was used without any further purification.

Et<sub>3</sub>N (0.14 mL) and propionic anhydride (1 mmol) were added to a cold solution of above (5-methoxyquinolin-2-yl)methanamine in THF (6 mL), and the resulting mixture was stirred at room temperature for 1 h. The solvent was evaporated under reduced pressure, the residue was taken up in EtOAc, washed with a saturated aqueous solution of NaHCO<sub>3</sub> and with brine. After drying over Na<sub>2</sub>SO<sub>4</sub>, the solvent was

removed by distillation in vacuo and the residue was purified by silica gel flash chromatography (EtOAc as eluent) and crystallization. Beige solid, mp 117–8 °C (CH<sub>2</sub>Cl<sub>2</sub>–petroleum ether); 48% yield. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 1.26 (t, 3H, J = 7.5 Hz), 2.40 (q, 2H, J = 7.5 Hz), 4.01 (s, 3H), 4.73 (d, 2H, J = 4.5 Hz), 6.84–6.89 (m, 1H), 7.20 (br s, 1H), 7.31 (d, 1H, J = 8.5 Hz), 7.61–7.65 (m, 2H), 8.54 (d, 1H, J = 8.5 Hz). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>) δ 173.9, 156.4, 155.2, 148.0, 131.7, 129.8, 120.7, 119.7, 119.1, 104.3, 55.7, 44.7, 29.7, 9.9. ESI MS (*m/z*): 245 (M + H)<sup>+</sup>.

**N-[(1-Benzyl-5-methoxy-1,2,3,4-tetrahydroquinolin-2-yl)methyl]propionamide (8a).** This product was obtained starting from **6a** and using the above N<sup>1</sup>-benzylation procedure described for compound **6n**. Flash chromatography: silica gel, EtOAc–cyclohexane 7:3 as eluent and crystallization. White solid, mp 154–5 °C (CH<sub>2</sub>Cl<sub>2</sub>–petroleum ether); 89% yield. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 1.04 (t, 3H, J = 7.5 Hz), 1.85–2.05 (m, 4H), 2.44–2.62 (m, 1H), 2.80–2.96 (m, 1H), 3.26–3.41 (m, 2H), 3.43–3.55 (m, 1H), 3.81 (s, 3H), 4.48 (d, 1H, J = 17.0 Hz), 4.64 (d, 1H, J = 17.0 Hz), 5.45 (br s, 1H), 6.28 (d, 1H, J = 8.0 Hz), 6.32 (d, 1H, J = 8.0 Hz), 6.99 (dd, 1H, J<sub>1</sub> = J<sub>2</sub> = 8.0 Hz), 7.23–7.37 (m, 5H). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>) δ 173.9, 157.3, 145.2, 139.7, 128.4, 126.8, 126.7, 126.5, 109.5, 106.2, 98.6, 56.8, 56.5, 55.4, 41.1, 29.5, 23.9, 23.3, 9.7. ESI MS (*m/z*): 339 (M + H)<sup>+</sup>.

**N-(1-Benzyl-6-methoxy-1,2,3,4-tetrahydroquinolin-2-yl)methylpropionamide (8b).** This product was obtained starting from **6b** and using the above N<sup>1</sup>-benzylation procedure described for compound **6n**. Flash chromatography: silica gel, EtOAc/cyclohexane 1:1 as eluent and crystallization. White solid, mp 147–8 °C (EtOAc–hexane); 78% yield. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 1.02 (t, 3H, J = 7.5 Hz), 1.90–2.05 (m, 4H), 2.72–2.85 (m, 2H), 3.14–3.47 (m, 3H), 3.74 (s, 3H), 4.39 (d, 1H, J = 16.5 Hz), 4.54 (d, 1H, J = 16.5 Hz), 5.45 (br s, 1H), 6.61–6.64 (m, 3H), 7.23–7.39 (m, 5H). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>) δ 173.8, 151.6, 139.8, 139.1, 128.7, 127.1, 127.0, 124.0, 115.5, 114.5, 112.9, 57.3, 57.0, 55.7, 41.2, 29.6, 24.2, 23.0, 9.7. ESI MS (*m/z*): 338 (M<sup>+</sup>), 91 (100).

**N-[(1-Benzyl-7-methoxy-1,2,3,4-tetrahydroquinolin-2-yl)methyl]propionamide (8c).** This product was obtained starting from **6c** and using the above N<sup>1</sup>-benzylation procedure described for compound **6n**. Flash chromatography: silica gel, EtOAc–cyclohexane 7:3 as eluent and crystallization. White solid, mp 129–30 °C (EtOAc–petroleum ether); 90% yield. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 1.05 (t, 3H, J = 7.5 Hz), 1.90–2.10 (m, 4H), 2.67–2.91 (m, 2H), 3.35 (t, 1H, J = 6.2 Hz), 3.51–3.57 (m, 1H), 3.67 (s, 3H), 4.52 (d, 1H, J = 17.2 Hz), 4.64 (d, 1H, J = 17.2 Hz), 5.47 (brs, 1H), 6.15 (d, 1H, J = 2.0 Hz), 6.23 (dd, 1H, J = 8.2 Hz), 6.94 (d, 1H, J = 8.2 Hz), 7.20–7.37 (m, 5H). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>) δ 174.0, 159.2, 145.4, 139.1, 129.5, 128.7, 127.0, 126.5, 114.6, 101.2, 99.2, 57.3, 55.4, 55.1, 41.4, 29.5, 23.6, 23.0, 9.7. ESI MS (*m/z*): 339 (M + H)<sup>+</sup>.

**N-[(1-Benzyl-1,2,3,4-tetrahydroquinolin-2-yl)methyl]propionamide (8d).** This product was obtained starting from **6d** and using the above N<sup>1</sup>-benzylation procedure described for compound **6n**. Flash chromatography: silica gel, EtOAc–cyclohexane 7:3 as eluent and crystallization. White solid, mp 108–9 °C (Et<sub>2</sub>O–petroleum ether); 92% yield. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 1.05 (t, 3H, J = 7.5 Hz), 1.92–2.08 (m, 4H), 2.73–2.93 (m, 2H), 3.32–3.40 (m, 2H), 3.43–3.59 (m, 1H), 4.53 (d, 1H, J = 17.0 Hz), 4.66 (d, 1H, J = 17.0 Hz), 5.47 (br s, 1H), 6.56–6.69 (m, 2H), 6.98–7.05 (m, 2H), 7.21–7.38 (m, 5H). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>) δ 173.9, 144.6, 139.3, 129.1, 128.7, 127.3, 127.0, 126.6, 122.1, 116.7, 113.0, 57.5, 55.6, 41.5, 29.6, 23.9, 23.3, 9.7. ESI MS (*m/z*): 309 (M + H)<sup>+</sup>.

**N-[(1-Benzyl-1,2,3,4-tetrahydroquinolin-2-yl)methyl]acetamide (8e).** This product was obtained starting from **6e** and using the above N<sup>1</sup>-benzylation procedure described for compound **6n**. Flash chromatography: silica gel, EtOAc as eluent and crystallization. Greyish solid, mp 120–1 °C (Et<sub>2</sub>O–petroleum ether); 59% yield. <sup>1</sup>H NMR (600 MHz, CD<sub>3</sub>OD) δ 1.84 (tt, 1H, J<sub>1</sub> = J<sub>2</sub> = 4.8, J<sub>3</sub> = J<sub>4</sub> = 13.2, H<sub>3B</sub>), 1.85 (s, 3H, CH<sub>3</sub>), 1.96 (ddd, 1H, J<sub>1</sub> = J<sub>2</sub> = 3.0, J<sub>3</sub> = 5.4, J<sub>4</sub> = 13.2 Hz, H<sub>3A</sub>), 2.65 (ddd, 1H, J<sub>1</sub> = J<sub>2</sub> = 3.6, J<sub>3</sub> = 16.2 Hz, H<sub>4B</sub>), 2.87 (ddd, 1H, J = 5.4, 13.2, 16.2 Hz, H<sub>4A</sub>), 3.18 (dd, 1H, J = 9.0, 13.2 Hz, H<sub>10B</sub>), 3.32 (dd, 1H, J = 4.8, 13.2 Hz, H<sub>10A</sub>), 3.49 (dq, 1H, J<sub>1</sub> = J<sub>2</sub> = J<sub>3</sub> = 4.2, J<sub>4</sub> = 7.8 Hz, H<sub>2</sub>), 4.52 (1/2ABq, 1H, J = 17.4 Hz, H<sub>9B</sub>), 4.61 (1/

2ABq, 1H, J = 17.4 Hz, 1H, H<sub>9A</sub>), 6.37 (d, J = 7.8 Hz, 1H, H<sub>8</sub>), 6.46 (td, 1H, J<sub>1</sub> = J<sub>2</sub> = 7.2, J<sub>3</sub> = 0.6 Hz, H<sub>6</sub>), 6.81 (bt, 1H, J<sub>1</sub> = J<sub>2</sub> = 7.8 Hz, H<sub>7</sub>), 6.89 (d, 1H, J = 7.2 Hz, H<sub>5</sub>), 7.12–7.15 (m, 1H, Ph), 7.18–7.24 (m, 4H, Ph). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>) δ 170.2, 144.6, 139.3, 129.1, 128.7, 127.2, 127.0, 126.7, 122.0, 116.7, 113.1, 57.3, 55.7, 41.6, 23.8, 23.3, 23.1. EI MS (*m/z*) 294 (M<sup>+</sup>), 91 (100).

<sup>1</sup>H NMR and NOESY spectra of compound **8e** are depicted in Supporting Information Figures S3 and S4. A description of the <sup>1</sup>H NMR spectrum can be found at page S6 of the Supporting Information.

Milligram-scale optical resolution of (±)-**8e** by MPLC, using triacetylcellulose (TAC) as chiral stationary phase,<sup>31</sup> afforded optical isomers (+)-**8e** and (–)-**8e**.

**Compound (+)-8e.** [ $\alpha$ ]<sub>D</sub><sup>25</sup> = +74.3 at λ = 365 nm (Hg lamp), (c 0.152 in abs EtOH); *t*<sub>R</sub> = 17.09 min [97% enantiomeric purity, as determined by analytical HPLC analysis on a Chiralcel (Chiralpak) AD-H column, using hexane–i-PrOH 9:1 as eluent, at 262 nm and a flow rate = 1.0 mL/min].

**Compound (–)-8e.** [ $\alpha$ ]<sub>D</sub><sup>25</sup> = –74.8 at λ = 365 nm (Hg lamp), (c 0.096 in abs EtOH); *t*<sub>R</sub> = 19.5 min [98% enantiomeric purity; Chiralcel (Chiralpak) AD-H column, hexane–i-PrOH 9:1 as eluent, at 262 nm and a flow rate = 1.0 mL/min].

**N-[(1-Benzyl-1,2,3,4-tetrahydroquinolin-2-yl)methyl]cyclopropanecarboxamide (8f).** This product was obtained starting from **6f** and using the above N<sup>1</sup>-benzylation procedure described for compound **6n**. Flash chromatography: silica gel, cyclohexane–EtOAc 7:3 as eluent and crystallization. White solid, mp 158–9 °C (CH<sub>2</sub>Cl<sub>2</sub>–petroleum ether); 58% yield. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 0.62–0.71 (m, 2H), 0.83–0.93 (m, 2H), 1.02–1.15 (m, 1H), 1.92–2.01 (m, 2H), 2.72–2.97 (m, 2H), 3.33–3.39 (m, 2H), 3.49–3.56 (m, 1H), 4.54 (d, 1H, J = 17.3 Hz), 4.66 (d, 1H, J = 17.3 Hz), 5.62 (br s, 1H), 6.56 (d, 1H, J = 8.0 Hz), 6.63 (ddd, 1H, J<sub>1</sub> = 1, J<sub>2</sub> = J<sub>3</sub> = 7.5 Hz), 6.96–7.04 (m, 2H), 7.22–7.36 (m, 5H). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>) δ 173.8, 144.5, 139.3, 129.1, 128.7, 127.2, 126.9, 126.6, 122.0, 116.5, 112.7, 57.5, 55.4, 41.7, 23.9, 23.3, 14.6, 7.1. ESI MS (*m/z*): 321 (M + H)<sup>+</sup>.

**N-[(1-Benzyl-1,2,3,4-tetrahydroquinolin-2-yl)methyl]cyclobutanecarboxamide (8g).** This product was obtained starting from **6g** and using the above N<sup>1</sup>-benzylation procedure described for compound **6n**. Flash chromatography: silica gel, cyclohexane–EtOAc 7:3 as eluent and crystallization. Amorphous solid; 54% yield. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 1.69–2.23 (m, 8H), 2.70–2.92 (m, 3H), 3.32–3.38 (m, 2H), 3.48–3.55 (m, 1H), 4.53 (d, 1H, J = 17.2 Hz), 4.64 (d, 1H, J = 17.2 Hz), 5.38 (br s, 1H), 6.54 (d, 1H, J = 8.2 Hz), 6.96–7.04 (m, 2H), 7.23–7.36 (m, 5H arom). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>) δ 175.1, 144.6, 139.2, 129.0, 128.7, 127.2, 126.9, 126.5, 122.0, 116.5, 112.7, 57.5, 55.4, 41.5, 39.8, 25.2, 23.9, 23.4, 18.0. ESI MS (*m/z*): 335 (M + H)<sup>+</sup>.

**N-[(1-Methyl-5-methoxy-1,2,3,4-tetrahydroquinolin-2-yl)methyl]propionamide (8h).** This product was obtained starting from **6a** and using the above N<sup>1</sup>-methylation procedure described for compound **6l**. Flash chromatography: silica gel, EtOAc as eluent and crystallization. White solid, mp 139–40 °C (CH<sub>2</sub>Cl<sub>2</sub>–petroleum ether); 87% yield. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 1.15 (t, 3H, J = 7.5 Hz), 1.84–1.89 (m, 2H), 2.21 (q, 2H, J = 7.5 Hz), 2.40–2.58 (m, 1H), 2.77–2.90 (m, 1H), 3.02 (s, 3H), 3.20–3.50 (m, 3H), 3.80 (s, 3H), 5.63 (br s, 1H), 6.27–6.33 (m, 2H), 7.08 (dd, 1H, J<sub>1</sub> = J<sub>2</sub> = 8.0 Hz). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>) δ 174.1, 157.1, 145.8, 127.0, 109.5, 104.7, 98.8, 57.2, 55.4, 40.6, 39.1, 29.7, 22.7, 17.0, 9.8. ESI MS (*m/z*): 263 (M + H)<sup>+</sup>.

**N-[(1-Methyl-1,2,3,4-tetrahydroquinolin-2-yl)methyl]propionamide (8i).** This product was obtained starting from **6d** and using the above N<sup>1</sup>-methylation procedure described for compound **6l**. Flash chromatography: silica gel, CH<sub>2</sub>Cl<sub>2</sub>–acetone 9:1 as eluent and crystallization. White solid, mp 63–4 °C (Et<sub>2</sub>O–petroleum ether); 95% yield. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 1.15 (t, 3H, J = 7.5), 1.81 (dddd, 1H, J<sub>1</sub> = 4.5, J<sub>2</sub> = 5.0, J<sub>3</sub> = J<sub>4</sub> = 13.0, H<sub>3B</sub>), 1.96 (dddd, 1H, J<sub>1</sub> = J<sub>2</sub> = 3.0, J<sub>3</sub> = 5.5, J<sub>4</sub> = 13.0, H<sub>3A</sub>), 2.23 (q, 2H, J = 7.5), 2.65 (ddd, 1H, J<sub>1</sub> = 3.0, J<sub>2</sub> = 5.0, J<sub>3</sub> = 16.5 Hz, H<sub>4B</sub>), 2.86 (ddd, 1H, J = 5.5, 13.0, 16.5 Hz, H<sub>4A</sub>), 3.01 (s, 3H, N-CH<sub>3</sub>), 3.19 (m, 1H, H<sub>10B</sub>), 3.36–3.41 (m, 1H, H<sub>10A</sub>), 3.43 (dddd, 1H, J = 3.0, 4.5, 5.0, 9 Hz, H<sub>2</sub>), 6.55 (ddd, 1H, J



= 1.0, 7.0, 7.5 Hz, ArH), 6.56 (d, 1H,  $J$  = 8.5, ArH), 6.92 (d, 1H,  $J$  = 7.0, ArH), 7.02 (ddd, 1H,  $J$  = 1.0, 7.5, 8.5, ArH).  $^{13}\text{C}$  NMR (50 MHz,  $\text{CDCl}_3$ )  $\delta$  174.1, 145.1, 128.7, 127.3, 122.0, 116.0, 111.0, 57.6, 41.1, 38.3, 29.7, 23.9, 23.5, 9.8. EI MS ( $m/z$ ): 232 ( $M^+$ ), 146 (100).

$^1\text{H}$  NMR and NOESY spectra of compound **8i** are depicted in Supporting Information Figures S6 and S7.

**N-[(1-Phenethyl-1,2,3,4-tetrahydroquinolin-2-yl)methyl]acetamide (8j).** A solution of **6e** (0.204 g, 1 mmol),  $\text{Et}_3\text{N}$  (0.27 mL), and phenylethyl bromide (0.54 mL, 4 mmol) in dry toluene (5 mL) and dry DMF (1 mL) was heated at 90 °C for 18 h. After cooling to room temperature, the reaction mixture was poured into water and extracted with EtOAc (3 $\times$ ); the combined organic phases were washed with brine and dried ( $\text{Na}_2\text{SO}_4$ ). After removing the solvent by distillation under reduced pressure, the residue was purified by silica gel flash chromatography (EtOAc as eluent). Amorphous solid; 68% yield.  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ )  $\delta$  1.63–1.85 (m, 2H), 1.96 (s, 3H), 2.63–2.92 (m, 4H), 3.26–3.50 (m, 4H), 3.68–3.83 (m, 1H), 5.56 (br s, 1H), 6.65 (dd, 1H  $J$  = 7.0, 7.5 Hz), 6.76 (d, 1H  $J$  = 8.0 Hz), 7.01 (d, 1H  $J$  = 7.5 Hz), 7.09–7.36 (m, 6H).  $^{13}\text{C}$  NMR (50 MHz,  $\text{CDCl}_3$ )  $\delta$  170.3, 143.4, 139.4, 129.4, 128.8, 128.5, 127.3, 126.3, 122.1, 116.1, 111.8, 56.3, 52.7, 41.3, 33.3, 23.7, 23.3, 23.0. EI MS ( $m/z$ ): 308 ( $M^+$ ), 236 (100).

**N-[(1-Propyl-1,2,3,4-tetrahydroquinolin-2-yl)methyl]acetamide (8k).** This product was prepared according to the above-described procedure for **8j** starting from **6e** and using 1-iodopropane instead of phenylethyl bromide as alkylating reagent. Flash chromatography: silica gel, EtOAc as eluent and crystallization. White solid, mp 106–7 °C ( $\text{CH}_2\text{Cl}_2$ –petroleum ether); 43% yield.  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ )  $\delta$  0.92 (t, 3H  $J$  = 7.5 Hz), 1.54–1.66 (m, 2H), 1.75–1.91 (m, 2H), 1.99 (s, 3H), 2.69–2.79 (m, 2H), 3.03–3.51 (m, 5H), 5.66 (br s, 1H), 6.56–6.64 (m, 2H), 6.98 (d, 1H  $J$  = 9.0 Hz), 7.07 (ddd, 1H  $J$  = 1.5, 8.5, 9.0 Hz).  $^{13}\text{C}$  NMR (50 MHz,  $\text{CDCl}_3$ )  $\delta$  170.4, 144.0, 129.2, 127.1, 121.7, 115.8, 112.0, 56.2, 53.0, 41.2, 23.6, 23.3, 22.9, 20.4, 11.4. EI MS ( $m/z$ ): 246 ( $M^+$ ), 174 (100).

**N-[(1-(2-Methylamino)-2-oxoethyl)-1,2,3,4-tetrahydroquinolin-2-yl]methylpropionamide (8l).** 2-Chloro-*N*-methylacetamide<sup>32</sup> (0.162 g, 1.5 mmol) was added to a solution of **6d** (0.218 g, 1 mmol) and  $\text{Et}_3\text{N}$  (0.21 mL, 1.5 mmol) in dry DMF (2 mL), and the resulting mixture was stirred under nitrogen at 100 °C for 16 h. The reaction mixture was poured into water and extracted with EtOAc. The organic phases were combined, washed with brine, dried ( $\text{Na}_2\text{SO}_4$ ), and the solvent evaporated under reduced pressure to give a crude product which was purified by flash chromatography (cyclohexane–acetone 1:1 as eluent) and crystallization. Beige solid, mp 168–70 °C (EtOAc–petroleum ether); 26% yield.  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ )  $\delta$  1.14 (t, 3H  $J$  = 7.5 Hz), 1.59–2.02 (m, 2H), 2.21 (q, 2H  $J$  = 7.5 Hz), 2.78–2.90 (m, 5H), 3.35–3.48 (m, 3H), 3.89 (d, 1H  $J$  = 17.0 Hz), 3.92 (d, 1H  $J$  = 17.0 Hz), 6.21 (br s, 1H), 6.32 (br s, 1H), 6.45 (d, 1H (d, 1H  $J$  = 8.0 Hz), 6.74 (dd, (d, 1H  $J_1 \approx J_2$  = 7.0 Hz), 7.02–7.12 (m, 2H). ESI MS ( $m/z$ ): 290 ( $M + \text{H}^+$ ).

**1,2,3,4-Tetrahydroquinoline-2-carbonitrile<sup>22</sup> (9).**  $\text{NaCNBH}_3$  (0.283 g, 4.5 mmol) was added portionwise under nitrogen and during 5 min to a solution of quinolin-2-carbonitrile (1 mmol) in AcOH (6 mL), and the resulting mixture was stirred at 40 °C for 16 h. The reaction mixture was quenched with water, adjusted to pH 11 by adding 30% NaOH, and the aqueous phase was extracted with  $\text{CH}_2\text{Cl}_2$  (3 $\times$ ). The combined organic layers were dried ( $\text{Na}_2\text{SO}_4$ ) and evaporated under reduced pressure to afford a crude residue which was purified by silica gel flash chromatography (cyclohexane–EtOAc 8:2 as eluent). Oil; 48% yield.  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ )  $\delta$  2.17–2.29 (m, 2H), 2.77–2.88 (m, 1H), 3.03–3.20 (m, 1H), 4.16 (br s, 1H), 4.42–4.46 (m, 1H), 6.56 (dd, 1H  $J$  = 1.0 and 8.0 Hz), 6.77 (ddd, 1H  $J$  = 1.0, 7.0, and 7.5 Hz), 7.02–7.09 (m, 2H). EI MS ( $m/z$ ): 158 ( $M^+$ ) 130 (100).

**1-Phenyl-1,2,3,4-tetrahydroquinoline-2-carbonitrile (10).** Cesium fluoride (0.22 g, 1.44 mmol) was added to a solution of **9** (0.16 g, 1 mmol) and 2-(trimethylsilyl)phenyl trifluoromethanesulfonate (0.125 mL, 0.84 mmol) in  $\text{CH}_3\text{CN}$  (13 mL), and the resulting mixture was stirred at room temperature for 16 h. The reaction mixture was quenched with water and then extracted with EtOAc (3 $\times$ ). The

combined organic phases were dried over  $\text{Na}_2\text{SO}_4$  and evaporated under reduced pressure to give a crude oily residue which was purified by silica gel flash chromatography (cyclohexane–EtOAc 9:1 as eluent). Oil; 55% yield.  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ )  $\delta$  2.21–2.38 (m, 2H), 2.77–2.82 (m, 1H), 3.07–3.31 (m, 1H), 4.54 (m, 1H), 6.38 (d, 1H  $J$  = 8.0 Hz), 6.69 ( $J_1 \approx J_2$  = 7.5 Hz), 6.81–7.39 (m, 7H). ESI MS ( $m/z$ ): 235 ( $M + \text{H}^+$ ).

**N-[(1-Phenyl-1,2,3,4-tetrahydroquinolin-2-yl)methyl]propionamide (11).** A solution of **10** (0.234 g, 1 mmol) in THF (5 mL) and propionic anhydride (1.2 mL, 9 mmol) was hydrogenated (4 atm) over Raney nickel for 5 h at 60 °C. The catalyst was filtered on Celite, the filtrate was concentrated in vacuo, and the residue was partitioned between EtOAc and water. The organic phase was washed with brine, dried ( $\text{Na}_2\text{SO}_4$ ), and evaporated under reduced pressure to give the crude desired product which was purified by crystallization. Beige solid, mp 86–7 °C ( $\text{Et}_2\text{O}$ –petroleum ether); 69% yield.  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ )  $\delta$  1.14 (t, 3H,  $J$  = 7.5 Hz), 1.93–2.17 (m, 2H), 2.25 (q, 2H,  $J$  = 7.5 Hz), 2.82–2.90 (m, 2H), 3.19–3.32 (m, 1H), 3.47–3.61 (m, 1H), 3.92–4.03 (m, 1H), 5.66 (br s, 1H), 6.71–6.83 (m, 2H), 6.93–7.02 (m, 1H), 7.06–7.37 (m, 6H).  $^{13}\text{C}$  NMR (50 MHz,  $\text{CDCl}_3$ )  $\delta$  173.9, 148.6, 142.8, 129.6, 129.5, 126.5, 124.9, 124.7, 123.9, 119.5, 118.8, 58.5, 41.2, 29.7, 23.7, 23.5, 9.8. EI MS ( $m/z$ ) 294 ( $M^+$ ), 208 (100).

**1-Methyl-1,2,3,4-tetrahydroquinoline-2-carbonitrile<sup>23</sup> (12).** Sodium cyanoborohydride (0.08 g, 1.3 mmol) and a 37% aqueous solution of HCHO (0.5 mL) were added to a solution of **9** (0.5 mmol) in MeOH (3 mL) and AcOH (to pH = 5), and the resulting mixture was stirred at room temperature for 16 h. An aqueous solution of 30% NaOH was added, and the aqueous phase was extracted with EtOAc. After drying over  $\text{Na}_2\text{SO}_4$ , the combined organic layers were concentrated by distillation under reduced pressure to give a crude residue which was purified by filtration on silica gel (cyclohexane–EtOAc 8:2 as eluent). Oil; 58% yield.  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ )  $\delta$  2.25–2.35 (m, 2H), 2.79–2.89 (m, 1H), 3.01 (s, 3H), 3.07–3.25 (m, 1H), 4.29–4.33 (m, 1H), 6.70–6.83 (m, 2H), 6.71 (d, 1H,  $J$  = 7.5 Hz) 7.16 (dd, 1H,  $J$  = 7.5 and 8.0 Hz). EI MS ( $m/z$ ): 172 ( $M^+$ , 100).

**1-Ethyl-3-[(1-methyl-1,2,3,4-tetrahydroquinolin-2-yl)methyl]thiourea (13).** A solution of **12**<sup>23</sup> (1 mmol) in THF (5 mL) and 2 M  $\text{NH}_3$  in EtOH (0.6 mL) was hydrogenated over Raney nickel (4 atm) for 2 h at room temperature. The catalyst was filtered on Celite, the filtrate was concentrated in vacuo, and the residue was partitioned between EtOAc and water. The organic phase was washed with brine, dried ( $\text{Na}_2\text{SO}_4$ ), and evaporated under reduced pressure to give the corresponding crude (1-methyl-1,2,3,4-tetrahydroquinolin-2-yl)-methanamine which was used without any further purification. Ethyl isothiocyanate (1 mmol) was added to a cold solution of the crude (1-methyl-1,2,3,4-tetrahydroquinolin-2-yl)methanamine in  $\text{CH}_2\text{Cl}_2$  (6 mL), and the resulting mixture was stirred at room temperature for 16 h. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel flash chromatography (cyclohexane–EtOAc 7:3 as eluent) and crystallization. White solid, mp 94–5 °C ( $\text{Et}_2\text{O}$ –petroleum ether); 52% yield.  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ )  $\delta$  1.17 (t, 3H  $J$  = 7.5 Hz), 1.90–1.95 (m, 2H), 2.73–2.79 (m, 2H), 3.04 (s, 3H), 3.18–3.37 (m, 2H), 3.51–3.68 (m, 3H), 5.84 (br s, 1H), 5.98 (br s, 1H), 6.63–6.71 (m, 2H), 7.01 (d, 1H  $J$  = 7.0 Hz), 7.13 (dd, 1H  $J_2$  = 7.5 and 8.0 Hz).  $^{13}\text{C}$  NMR (50 MHz,  $\text{CDCl}_3$ )  $\delta$  181.8, 144.9, 128.9, 127.4, 122.3, 116.7, 111.9, 57.5, 46.5, 38.8, 36.3, 24.0, 23.7, 14.0. ESI MS ( $m/z$ ): 264 ( $M + \text{H}^+$ ).

**N-[2-(1,2,3,4-Tetrahydroquinolin-2-yl)ethyl]propionamide (14).** A solution of (1,2,3,4-tetrahydroquinolin-2-yl)acetonitrile<sup>24</sup> (1 mmol) in THF (5 mL) and 2 M  $\text{NH}_3$  in EtOH (0.6 mL) was hydrogenated over Raney nickel (4 atm) for 6 h at 60 °C. The catalyst was filtered on Celite, the filtrate was concentrated in vacuo, and the residue was partitioned between EtOAc and water. The organic phase was washed with brine, dried ( $\text{Na}_2\text{SO}_4$ ), and evaporated under reduced pressure to give the corresponding crude oily amine which was used without any further purification.

$\text{Et}_3\text{N}$  (0.14 mL) and propionic anhydride (1 mmol) were added to a cold solution of the above crude amine in THF (6 mL), and the resulting mixture was stirred at room temperature for 1 h. The solvent

was evaporated under reduced pressure, the residue was taken up in EtOAc, washed with a saturated aqueous solution of  $\text{NaHCO}_3$  and with brine. After drying over  $\text{Na}_2\text{SO}_4$ , the solvent was removed by distillation in vacuo to give a crude product that was purified by flash chromatography:

EtOAc as eluent. Oil; 57% yield.  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ )  $\delta$  1.20 (t, 3H  $J$  = 7.5 Hz), 1.59–1.78 (m, 3H), 1.92–2.01 (m, 1H), 2.22 (q, 2H  $J$  = 7.5 Hz), 2.68–2.82 (m, 2H), 3.20–3.39 (m, 2H), 3.52–3.69 (m, 1H), 5.72 (br s, 1H), 6.53–6.66 (m, 2H), 6.94–7.02 (m, 2H). EI MS ( $m/z$ ): 232 ( $M^+$ ), 132 (100).

*N*-[2-(1-Benzyl-1,2,3,4-tetrahydroquinolin-2-yl)ethyl]-propionamide (**15**). This product was obtained starting from **14** and using the previous *N*<sup>1</sup>-benzylation procedure described for compound **6n**. The crude product was purified by silica gel flash chromatography: cyclohexane–EtOAc 3:7 as eluent. Beige solid, mp 66–7 °C ( $\text{Et}_2\text{O}$ –petroleum ether); 70% yield.  $^1\text{H}$  NMR (200 MHz,  $\text{CDCl}_3$ )  $\delta$  1.10 (t, 3H  $J$  = 7.5 Hz), 1.61–2.02 (m, 4H), 2.09 (q, 2H  $J$  = 7.5 Hz), 2.71–2.98 (m, 2H), 3.20–3.42 (m, 3H), 4.42 (d, 1H,  $J$  = 16.5 Hz), 4.53 (d, 1H,  $J$  = 16.5 Hz), 5.21 (br s, 1H), 6.55–6.68 (m, 2H), 6.98–7.05 (m, 2H), 7.23–7.39 (m, 5H).  $^{13}\text{C}$  NMR (50 MHz,  $\text{CDCl}_3$ )  $\delta$  173.8, 144.6, 139.2, 129.2, 128.6, 127.1, 127.0, 127.0, 122.2, 116.6, 113.4, 55.4, 54.8, 36.5, 31.8, 29.6, 24.1, 23.5, 9.9. EI MS ( $m/z$ ): 322 ( $M^+$ ), 91 (100).

**Optical Resolution of Compound ( $\pm$ )-8e.** Racemic ( $\pm$ )-**8e** was separated into its constituent enantiomers using a semipreparative column having triacetylcellulose (TAC) as a chiral stationary phase. A Büchi (Switzerland) borosilicate column (length, 40 cm; internal diameter, 3.0 cm) was filled with a slurry of 100 g of TAC in  $\text{EtOH}$ – $\text{H}_2\text{O}$  7:3 and packed following a previously described procedure.<sup>31</sup> Solvent delivery system, Gilson 307 pump; mobile phase,  $\text{EtOH}$ – $\text{H}_2\text{O}$  7:3; flow rate, 1 mL/min; sample concentration, 1.7% (w/v in  $\text{EtOH}$ ). Ultraviolet detection was achieved at 262 nm using a Waters Lambda-Max model 480 tunable absorbance detector. Fractions were collected using a Gilson FC 203B fraction collector (12 min/tube). The chromatograms were registered with a Linseis recorder (05.80 L) (range AUFS 2.0  $\times$  20 mV).

The enantiomeric purity of chromatographic fractions was determined by analytical HPLC analysis on a Chiralcel (Chiralpak) AD-H column, using hexane–*i*-PrOH 9:1 as eluent, at 262 nm and a flow rate = 1.0 mL/min. The chromatographic fractions showing a single enantiomer ( $\lambda$  = 262 nm:  $t_{\text{R}1}$  = 17.09 min;  $t_{\text{R}2}$  = 19.5 min) was collected and the others recombined and recycled through the TAC column. Repeating the procedure just described several times, it was possible to obtain an enriched fraction (ee >97%) for both enantiomers. The enantiomer enriched fractions were collected, evaporated under reduced pressure, and further purified by flash chromatography (silica gel, EtOAc as eluent) and crystallization ( $\text{Et}_2\text{O}$ –petroleum ether).

Optical rotation analysis was performed using a PerkinElmer 241 polarimeter using a Hg lamp ( $\lambda$  = 365 nm).  $\alpha$  values were determined at 25 °C and are reported in  $10^{-1}$  deg  $\text{cm}^2 \text{g}^{-1}$ ; concentration (*c*) is in g per 100 mL. Enantiomeric purity was determined by HPLC on the following apparatus: Shimadzu LC-10AT (liquid chromatograph), Shimadzu SPD-10A (UV detector), Shimadzu C-R6A Chromatopac, using Chiralcel AD-H as column.

**Pharmacology. Reagents and Chemicals.** 2-[ $^{125}\text{I}$ ]-Iodomelatonin (2200 Ci/mmol) was purchased from NEN (Boston, MA). Other drugs and chemicals were purchased from Sigma-Aldrich (Saint Quentin, France).

**Cell Culture.** CHO cell lines stably expressing the human melatonin  $\text{MT}_1$  or  $\text{MT}_2$  receptors were grown in DMEM medium supplemented with 10% fetal calf serum, 2 mM glutamine, 100 IU/mL penicillin, and 100  $\mu\text{g}/\text{mL}$  streptomycin. Grown at confluence at 37 °C (95%  $\text{O}_2$ /5%  $\text{CO}_2$ ), they were harvested in PBS containing EDTA 2 mM and centrifuged at 1000g for 5 min (4 °C). The resulting pellet was suspended in TRIS 5 mM (pH 7.5), containing EDTA 2 mM and homogenized using a Kinematica polytron. The homogenate was then centrifuged (95000g, 30 min, 4 °C), and the resulting pellet suspended in 75 mM TRIS (pH 7.5), 12.5 mM  $\text{MgCl}_2$ , and 2 mM EDTA. Aliquots of membrane preparations were stored at –80 °C until use.

**Binding Assays.** 2-[ $^{125}\text{I}$ ]-iodomelatonin binding assay conditions were essentially as previously described.<sup>33</sup> Briefly, binding was initiated by addition of membrane preparations from stable transfected CHO cells diluted in binding buffer (50 mM Tris-HCl buffer, pH 7.4, containing 5 mM  $\text{MgCl}_2$ ) to 2-[ $^{125}\text{I}$ ]-iodomelatonin (20 pM for  $\text{MT}_1$  and  $\text{MT}_2$  receptors) and the tested drug. Nonspecific binding was defined in the presence of 1  $\mu\text{M}$  melatonin. After 120 min incubation at 37 °C, reaction was stopped by rapid filtration through GF/B filters presoaked in 0.5% (v/v) polyethylenimine. Filters were washed three times with 1 mL of ice-cold 50 mM Tris-HCl buffer, pH 7.4.

Data from the dose–response curves (seven concentrations in duplicate) were analyzed using the program PRISM (Graph Pad Software Inc., San Diego, CA) to yield  $\text{IC}_{50}$  (inhibitory concentration 50). Results are expressed as  $K_i = \text{IC}_{50}/1 + ([L]/K_D)$ , where  $[L]$  is the concentration of radioligand used in the assay and  $K_D$  the dissociation constant of the radioligand characterizing the membrane preparation.<sup>34</sup>

**Functional Assays.** [ $^{35}\text{S}$ ]GTP $\gamma\text{S}$  binding assay was performed according to published methodology.<sup>33</sup> Briefly, membranes from transfected CHO cells expressing  $\text{MT}_1$  or  $\text{MT}_2$  receptor subtype and compounds were diluted in binding buffer (20 mM HEPES, pH 7.4, 100 mM NaCl, 3  $\mu\text{M}$  GDP, 3 mM  $\text{MgCl}_2$ , and 20  $\mu\text{g}/\text{mL}$  saponin). Incubation was started by the addition of 0.2 nM [ $^{35}\text{S}$ ]GTP $\gamma\text{S}$  to membranes (20  $\mu\text{g}/\text{mL}$ ) and drugs and further followed for 1 h at room temperature. Nonspecific binding was defined using cold GTP $\gamma\text{S}$  (10  $\mu\text{M}$ ). Reaction was stopped by rapid filtration through GF/B filters followed by three successive washes with ice-cold buffer.

Usual levels of [ $^{35}\text{S}$ ]GTP $\gamma\text{S}$  binding (expressed in dpm) were for CHO- $\text{MT}_1$  or  $\text{MT}_2$  membranes: 2000 for basal activity, 8000 in the presence of melatonin 1  $\mu\text{M}$ , and 180 in the presence of GTP $\gamma\text{S}$  10  $\mu\text{M}$  which defined the nonspecific binding. Data from the dose–response curves (seven concentrations in duplicate) were analyzed by using the program PRISM (Graph Pad Software Inc., San Diego, CA) to yield  $\text{EC}_{50}$  (effective concentration 50%) and  $E_{\text{max}}$  (maximal effect) for agonists.

**Molecular Modeling.** Compounds **8e** and **6d** were built in Maestro 9.6<sup>35</sup> and minimized with MacroModel 10.2<sup>36</sup> by applying the OPLS2005 force field<sup>37</sup> and the GB/SA continuum solvation model for water<sup>38</sup> to an energy gradient of 0.05  $\text{kJ mol}^{-1} \text{\AA}^{-1}$ . The minimized structures were solvated with explicit TIP3P water or methanol molecules with Desmond 3.6,<sup>39</sup> placing simulation box boundaries 10 Å far from ligand atoms on each side. The resulting systems were first equilibrated by applying the default relaxation protocol implemented in Desmond 3.6 and then submitted to standard plain molecular dynamics (MD) or well-tempered metadynamics simulations by applying the Langevin coupling scheme<sup>40</sup> and setting temperature and pressure at 298 K and 1 atm, respectively. Plain MD simulation was carried out for 1  $\mu\text{s}$ , collecting one snapshot every 10 ps. For metadynamics simulations, dihedral angles  $\tau_1$  and  $\tau_2$  ( $\tau_1$ , N1–C2–C3–C4;  $\tau_2$ , C8a–N1–Cbn–Car, see legend of Figure 3) were chosen as the collective variables for compound **8e**, while for compound **6d** only  $\tau_1$  was considered. The initial height and width of the Gaussian potentials were set to 0.03  $\text{kcal mol}^{-1}$  and 2°, respectively, while the time interval between subsequent potentials was set to 0.09 ps.

The convergence of well-tempered metadynamics simulations was assessed by evaluating the time evolution of the relative free-energy levels of the free-energy minima (see Supporting Information Figures S9b and S10b). To this aim, well-tempered metadynamics were run for 50 ns, free-energy profiles were reconstructed after every ns, and the simulation was considered to be converged when free-energy differences among global and local minima became approximately constant. For both compounds **8e** and **6d**, metadynamics simulations converged approximately after 20 ns. Therefore, only the free-energy profiles obtained at 20 ns for compounds **8e** and **6d** are reported and discussed. The maximum free-energy values were truncated at 4 kcal/mol.



## ■ ASSOCIATED CONTENT

## ■ Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jmedchem.5b01066.

<sup>1</sup>H NMR spectra of compounds **8e**, **8i**, and **6d**, NOESY spectra of compounds **8e** and **8i**, free-energy surfaces obtained from plain molecular dynamics and metadynamics simulations of compounds **8e** and **6d**, purity of target compounds (PDF)

Molecular formula strings (CSV)

## ■ AUTHOR INFORMATION

## Corresponding Author

\*Phone: +39 0521 905061. Fax: + 39 0521 905006. E-mail: [silvia.rivara@unipr.it](mailto:silvia.rivara@unipr.it).

## Notes

The authors declare no competing financial interest.

## ■ ACKNOWLEDGMENTS

We are grateful to the Centro Interdipartimentale Misure "Giuseppe Casnati" of the University of Parma, Italy, for providing NMR instrumentation.

## ■ ABBREVIATIONS USED

DMEM, Dulbecco's Modified Eagle Medium;  $E_{\max}$ , maximum activation of receptor; GTP $\gamma$ S, guanosine 5'-O-(3-thiotriphosphate); MD, molecular dynamics; MPLC, medium-pressure liquid chromatography; MT<sub>1</sub>, melatonin receptor subtype 1; MT<sub>2</sub>, melatonin receptor subtype 2; NOE, nuclear Overhauser effect; NOESY, nuclear Overhauser effect spectroscopy; PBS, phosphate-buffered saline; TAC, triacetylcellulose; THF, tetrahydrofuran

## ■ REFERENCES

- (1) Hardeland, R.; Cardinali, D. P.; Srinivasan, V.; Spence, D. W.; Brown, G. M.; Pandi-Perumal, S. R. Melatonin—a pleiotropic, orchestrating regulator molecule. *Prog. Neurobiol.* **2011**, *93*, 350–384.
- (2) Altun, A.; Ugur-Altun, B. Melatonin: therapeutic and clinical utilization. *Int. J. Clin. Pract.* **2007**, *61*, 835–845.
- (3) Rivara, S.; Pala, D.; Bedini, A.; Spadoni, G. Therapeutic uses of melatonin and melatonin derivatives: a patent review (2012 - 2014). *Expert Opin. Ther. Pat.* **2015**, *25*, 425–441.
- (4) Sanchez-Barcelo, E. J.; Mediavilla, M. D.; Tan, D. X.; Reiter, R. J. Clinical uses of melatonin. *Curr. Med. Chem.* **2010**, *17*, 2070–2095.
- (5) Hardeland, R. Melatonin: signaling mechanisms of a pleiotropic agent. *BioFactors* **2009**, *35*, 183–192.
- (6) Dubocovich, M.; Markowska, M. Functional MT<sub>1</sub> and MT<sub>2</sub> melatonin receptors in mammals. *Endocr. J.* **2005**, *27*, 101–110.
- (7) Slominski, R. M.; Reiter, R. J.; Schlubritz-Loutsevitch, N.; Ostrom, R. S.; Slominski, A. T. Melatonin membrane receptors in peripheral tissues: distribution and functions. *Mol. Cell. Endocrinol.* **2012**, *351*, 152–166.
- (8) Lemoine, P.; Zisapel, N. Prolonged-release formulation of melatonin (Circadin) for the treatment of insomnia. *Expert Opin. Pharmacother.* **2012**, *13*, 895–905.
- (9) Hardeland, R.; Poeggeler, B.; Srinivasan, V.; Trakht, I.; Pandi-Perumal, S. R.; Cardinali, D. P. Melatonergic drugs in clinical practice. *Arzneim. Forsch.* **2008**, *58*, 1–10.
- (10) Dhillon, S.; Clarke, M. Tasimelteon: first global approval. *Drugs* **2014**, *74*, S05–S11.
- (11) Garratt, P. J.; Tsotinis, A. Synthesis of compounds as melatonin agonists and antagonists. *Mini-Rev. Med. Chem.* **2007**, *7*, 1075–1088.
- (12) Zlotos, D. P.; Jockers, R.; Cecon, E.; Rivara, S.; Witt-Enderby, P. A. MT<sub>1</sub> and MT<sub>2</sub> melatonin receptors: ligands, models, oligomers, and therapeutic potential. *J. Med. Chem.* **2014**, *57*, 3161–3185.
- (13) Tosini, G.; Owino, S.; Guillaume, J. L.; Jockers, R. Understanding melatonin receptor pharmacology: Latest insights from mouse models, and their relevance to human disease. *BioEssays* **2014**, *36*, 778–787.
- (14) Rivara, S.; Lodola, A.; Mor, M.; Bedini, A.; Spadoni, G.; Lucini, V.; Pannacci, M.; Fraschini, F.; Scaglione, F.; Sanchez, R. O.; Gobbi, G.; Tarzia, G. N-(Substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands. *J. Med. Chem.* **2007**, *50*, 6618–6626.
- (15) Rivara, S.; Pala, D.; Lodola, A.; Mor, M.; Lucini, V.; Dugnani, S.; Scaglione, F.; Bedini, A.; Lucarini, S.; Tarzia, G.; Spadoni, G. MT<sub>1</sub>-selective melatonin receptor ligands: Synthesis, pharmacological evaluation, and molecular dynamics investigation of N-[(3-O-substituted)anilino]alkyl amides. *ChemMedChem* **2012**, *7*, 1954–1964.
- (16) Spadoni, G.; Balsamini, C.; Diamantini, G.; Di Giacomo, B.; Tarzia, G.; Mor, M.; Plazzi, P. V.; Rivara, S.; Lucini, V.; Nonno, R.; Pannacci, M.; Fraschini, F.; Stankov, B. M. Conformationally restrained melatonin analogs: synthesis, binding affinity for the melatonin receptor, evaluation of the biological activity, and molecular modeling study. *J. Med. Chem.* **1997**, *40*, 1990–2002.
- (17) Rivara, S.; Diamantini, G.; Di Giacomo, B.; Lamba, D.; Gatti, G.; Lucini, V.; Pannacci, M.; Mor, M.; Spadoni, G.; Tarzia, G. Reassessing the melatonin pharmacophore-enantiomeric resolution, pharmacological activity, structure analysis, and molecular modeling of a constrained chiral melatonin Analogue. *Bioorg. Med. Chem.* **2006**, *14*, 3383–3391.
- (18) Rivara, S.; Mor, M.; Silva, C.; Zuliani, V.; Vacondio, F.; Spadoni, G.; Bedini, A.; Tarzia, G.; Lucini, V.; Pannacci, M.; Fraschini, F.; Plazzi, P. V. Three-dimensional quantitative structure-activity relationship studies on selected MT<sub>1</sub> and MT<sub>2</sub> melatonin receptor ligands: requirements for subtype selectivity and intrinsic activity modulation. *J. Med. Chem.* **2003**, *46*, 1429–1439.
- (19) Wang, T.; Wallace, O. B.; Meanwell, N. A.; Kadow, J. F.; Zhang, Z.; Yang, Z. Preparation of piperazine derivatives as antiviral agents. PCT Int. Appl. WO 2003092695 A1 20031113, 2003.
- (20) Hoekstra, W. J.; Schotzinger, R. J.; Rafferty, S. W. Metalloenzyme inhibitor compounds. U.S. Pat. Appl. US 20120149729 A1 20120614, 2012.
- (21) Hoegberg, S.; Elman, B.; Liem, H.; Madan, K.; Moberg, C.; Muhammed, M.; Sjoeborg, B.; Weber, M. Chelate-forming quinoline compounds and processes for recovering metals. PCT Int. Appl. WO8401947 A1 19840524, 1984.
- (22) Higgins, R. C.; Townsend, N. O.; Jackson, Y. A. Benzylic oxidation of N-acyl-1,2,3,4-tetrahydroquinoline. *Heterocycles* **2009**, *78*, 3011–3021.
- (23) Le Gall, E.; Hurvois, J. P.; Renaud, T.; Moinet, C.; Talleg, A.; Uriac, P.; Sinbandhit, S.; Toupet, L. Electrosynthesis of  $\alpha$ -amino nitriles. Anodic cyanation of N-substituted tetrahydroquinolines and N-phenylpiperidines. *Liebigs Ann./Recl.* **1997**, *1997*, 2089–2101.
- (24) Nagata, R.; Tanno, N.; Kodo, T.; Ae, N.; Yamaguchi, H.; Nishimura, T.; Antoku, F.; Tatsuno, T.; Kato, T.; Tanaka, Y.; Nakamura, M.; Ogita, K.; Yoneda, Y. Tricyclic quinoxalinediones: 5,6-dihydro-1H-pyrrolo[1,2,3-de] quinoxaline-2,3-diones and 6,7-dihydro-1H,5H-pyrrolo[1,2,3-de] quinoxaline-2,3-diones as potent antagonists for the glycine binding site of the NMDA receptor. *J. Med. Chem.* **1994**, *37*, 3956–3968.
- (25) Spadoni, G.; Balsamini, C.; Diamantini, G.; Tontini, A.; Tarzia, G.; Mor, M.; Rivara, S.; Plazzi, P. V.; Nonno, R.; Lucini, V.; Pannacci, M.; Fraschini, F.; Stankov, B. M. 2-N-acylaminoalkylindoles: design and quantitative structure-activity relationship studies leading to MT<sub>2</sub>-selective melatonin antagonists. *J. Med. Chem.* **2001**, *44*, 2900–2912.
- (26) Bedini, A.; Lucarini, S.; Spadoni, G.; Tarzia, G.; Scaglione, F.; Dugnani, S.; Pannacci, M.; Lucini, V.; Carmi, C.; Pala, D.; Rivara, S.; Mor, M. Toward the definition of stereochemical requirements for

MT<sub>2</sub>-selective antagonists and partial agonists by studying 4-phenyl-2-propionamidotetralin derivatives. *J. Med. Chem.* **2011**, *54*, 8362–8372.

(27) Wan, N.; Zhang, F.-F.; Ju, J.; Liu, D.-Z.; Zhou, S.-Y.; Zhang, B.-L. Investigational selective melatonineric ligands for receptor subtype MT<sub>2</sub>. *Mini-Rev. Med. Chem.* **2013**, *13*, 1462–1474.

(28) Ettaoussi, M.; Sabaoui, A.; Pérès, B.; Landagaray, E.; Nosjean, O.; Boutin, J. A.; Caignard, D.-H.; Delagrangé, P.; Berthelot, P.; Yous, S. Synthesis and pharmacological evaluation of a series of the agomelatine analogues as melatonin MT<sub>1</sub>/MT<sub>2</sub> agonist and 5-HT<sub>2C</sub> antagonist. *ChemMedChem* **2013**, *8*, 1830–1845.

(29) Koike, T.; Hoashi, Y.; Takai, T.; Nakayama, M.; Yukuhiro, N.; Ishikawa, T.; Hirai, K.; Uchikawa, O. 1,6-Dihydro-2H-indeno[5,4-b]furan derivatives: design, synthesis, and pharmacological characterization of a novel class of highly potent MT<sub>2</sub>-selective agonists. *J. Med. Chem.* **2011**, *54*, 3436–3444.

(30) Boger, D. L.; Brotherton, C. E.; Panek, J. S.; Yohannes, D. Direct introduction of nitriles via use of unstable Reissert intermediates: convenient procedures for the preparation of 2-cyanoquinolines and 1-cyanoisoquinolines. *J. Org. Chem.* **1984**, *49*, 4056–4058.

(31) Jansen, J. M.; Copinga, S.; Gruppen, G.; Isaksson, R.; Witte, D. T.; Grol, C. J. Semipreparative enantiomeric separation of a series of putative melatonin receptor agents using triacetylcellulose as chiral stationary phase. *Chirality* **1994**, *6*, 596–604.

(32) Musso, D. L.; Cochran, F. R.; Kelley, J. L.; McLean, E. W.; Selph, J. L.; Rigdon, G. C.; Orr, G. F.; Davis, R. G.; Cooper, B. R.; Styles, V. L.; Thompson, J. B.; Hall, W. R. Indanylidene. 1. Design and synthesis of (E)-2-(4,6-difluoro-1-indanylidene)acetamide, a potent centrally acting muscle relaxant with anti-inflammatory and analgesic activity. *J. Med. Chem.* **2003**, *46*, 399–408.

(33) Audinot, V.; Mailliet, F.; Lahaye-Brasseur, C.; Bonnaud, A.; Le Gall, A.; Amossé, C.; Dromaint, S.; Rodriguez, M.; Nagel, N.; Galizzi, J. P.; Malpoux, B.; Guillaumet, G.; Lesieur, D.; Lefoulon, F.; Renard, P.; Delagrangé, P.; Boutin, J. A. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **2003**, *367*, 553–561.

(34) Cheng, Y.-C.; Prusoff, W. H. Relationship between the inhibition constant ( $K_i$ ) and the concentration of inhibitor which causes 50% inhibition ( $I_{50}$ ) of an enzymatic reaction. *Biochem. Pharmacol.* **1973**, *22*, 3099–3108.

(35) *Maestro*, version 9.6; Schrödinger, LLC, New York, 2013.

(36) *MacroModel*, version 10.2; Schrödinger, LLC, New York, 2013.

(37) Banks, J. L.; Beard, H. S.; Cao, Y.; Cho, A. E.; Damm, W.; Farid, R.; Felts, A. K.; Halgren, T. A.; Mainz, D. T.; Maple, J. R.; Murphy, R.; Philipp, D. M.; Repasky, M. P.; Zhang, L. Y.; Berne, B. J.; Friesner, R. A.; Gallicchio, E.; Levy, R. M. Integrated Modeling Program, Applied Chemical Theory (IMPACT). *J. Comput. Chem.* **2005**, *26*, 1752–1780.

(38) Still, W. C.; Tempczyk, A.; Hawley, R. C.; Hendrickson, T. Semianalytical treatment of solvation for molecular mechanics and dynamics. *J. Am. Chem. Soc.* **1990**, *112*, 6127–6129.

(39) *Desmond Molecular Dynamics System*, version 3.6; D. E. Shaw Research: New York, 2013; *Maestro–Desmond Interoperability Tools*, version 3.6; Schrödinger: New York, 2013.

(40) Feller, S. E.; Zhang, Y.; Pastor, R. W.; Brooks, B. R. Constant pressure molecular dynamics simulation: The Langevin piston method. *J. Chem. Phys.* **1995**, *103*, 4613–4621.

(41) Landagaray, E.; Ettaoussi, M.; Leclerc, V.; Traoré, B.; Perez, V.; Nosjean, O.; Boutin, J. A.; Caignard, D.-H.; Delagrangé, P.; Berthelot, P.; Yous, S. New melatonin (MT<sub>1</sub>/MT<sub>2</sub>) ligands: Design and synthesis of (8,9-dihydro-7H-furo[3,2-f]chromen-1-yl) derivatives. *Bioorg. Med. Chem.* **2014**, *22*, 986–996.